39 results on '"Laura Tarancon-Diez"'
Search Results
2. Long-term evolution in liver disease markers and immune and lipid profiles in vertically HIV/HCV-coinfected youths with sustained viral response after direct-acting antivirals therapy
- Author
-
Laura Tarancon-Diez, Itzíar Carrasco, Santiago Jiménez de Ory, Arantxa Berzosa Sánchez, Alicia Hernanz-Lobo, Marta Montero-Alonso, Montserrat Laguno, Jose I. Bernardino, Luis López-Cortés, Teresa Aldamiz-Echevarría, Pilar Collado, Otilia Bisbal, Gloria Samperiz, César Gavilán, Mª José Ríos, Sofía Ibarra, María Luisa Navarro, and Mª Ángeles Muñoz-Fernández
- Subjects
Direct-acting antivirals ,Vertically acquired HIV/HCV-coinfection ,Hepatic profile ,Immune profile ,Lipid profile ,Therapeutics. Pharmacology ,RM1-950 - Abstract
This study aimed to analyse the long-term effect of direct-acting antivirals (DAAs) in vertically acquired HIV/HCV-coinfected youths. We performed a multicentre, longitudinal and observational study within the Spanish Cohort of HIV-infected children and adolescents and vertically HIV-infected patients transferred to Adult Units (CoRISpe-FARO). We included HIV/HCV-coinfected youths (n = 24) that received DAAs between 2015 and 2017 with successful sustained viral response (SVR) with a subsequent follow-up of at least three years. Long-term evolution in liver disease severity and haematologic markers, lipid and immune profiles after SVR were assessed. Study times were the start date of DAAs treatment (baseline, T0) and 1, 2, 3, 4 and 5 years after SVR (T1, T2, T3, T4 and T5, respectively). We observed global improvements in liver function data that persist over time and a favourable haematologic and immune outcome at the long-term including a constant augment in leucocytes, neutrophils, neutrophils to lymphocytes ratio (NLR) and CD4/CD8 ratio over-time. Regarding the lipid profile, we found a significant increase in total cholesterol T2, total cholesterol/high-density lipoprotein (HDL) ratio at T4, triglycerides at T5, low-density lipoprotein (LDL) over time, and a decrease in HDL in all patients but with marked higher levels in the subgroup receiving anti-HIV Protease Inhibitor (PI)-based regimens. Comparisons of vertically HIV/HCV-coinfected youths after SVR at 3-year follow-up and a control group of vertically HIV-monoinfected youths never infected by HCV showed no significant differences in most variables analysed, suggesting a possible normalization in all parameters.
- Published
- 2023
- Full Text
- View/download PDF
3. Toll-like receptor agonists enhance HIV-specific T cell response mediated by plasmacytoid dendritic cells in diverse HIV-1 disease progression phenotypesResearch in context
- Author
-
Maria R. Jimenez-Leon, Carmen Gasca-Capote, Laura Tarancon-Diez, Beatriz Dominguez-Molina, Macarena Lopez-Verdugo, Ryan Ritraj, Isabel Gallego, Ana I. Alvarez-Rios, Joana Vitalle, Sara Bachiller, María Inés Camacho-Sojo, Alberto Perez-Gomez, Nuria Espinosa, Cristina Roca-Oporto, Mohamed Rafii-El-Idrissi Benhnia, Alicia Gutierrez-Valencia, Luis F. Lopez-Cortes, and Ezequiel Ruiz-Mateos
- Subjects
Plasmacytoid dendritic cells ,TLR agonists ,HIV-Infection ,HIV-1 restriction factors and immunotherapy ,Medicine ,Medicine (General) ,R5-920 - Abstract
Summary: Background: Plasmacytoid dendritic cells (pDCs) sense viral and bacterial products through Toll-like receptor (TLR)-7 and -9 and translate this sensing into Interferon-α (IFN-α) production and T-cell activation. The understanding of the mechanisms involved in pDCs stimulation may contribute to HIV-cure immunotherapeutic strategies. The objective of the present study was to characterize the immunomodulatory effects of TLR agonist stimulations in several HIV-1 disease progression phenotypes and in non HIV-1 infected donors. Methods: pDCs, CD4 and CD8 T-cells were isolated from 450 ml of whole blood from non HIV-1 infected donors, immune responders (IR), immune non responders (INR), viremic (VIR) and elite controller (EC) participants. pDCs were stimulated overnight with AT-2, CpG-A, CpG-C and GS-9620 or no stimuli. After that, pDCs were co-cultured with autologous CD4 or CD8 T-cells and with/without HIV-1 (Gag peptide pool) or SEB (Staphylococcal Enterotoxin B). Cytokine array, gene expression and deep immunophenotyping were assayed. Findings: pDCs showed an increase of activation markers levels, interferon related genes, HIV-1 restriction factors and cytokines levels after TLR stimulation in the different HIV-disease progression phenotypes. This pDC activation was prominent with CpG-C and GS-9620 and induced an increase of HIV-specific T-cell response even in VIR and INR comparable with EC. This HIV-1 specific T-cell response was associated with the upregulation of HIV-1 restriction factors and IFN-α production by pDC. Interpretation: These results shed light on the mechanisms associated with TLR-specific pDCs stimulation associated with the induction of a T-cell mediated antiviral response which is essential for HIV-1 eradication strategies. Funding: This work was supported by Gilead fellowship program, the Instituto de Salud Carlos III (Fondo Europeo de Desarrollo Regional, FEDER, “a way to make Europe”) and the Red Temática de Investigación Cooperativa en SIDA and by the Spanish National Research Council (CSIC).
- Published
- 2023
- Full Text
- View/download PDF
4. Immunoescape of HIV-1 in Env-EL9 CD8 + T cell response restricted by HLA-B*14:02 in a Non progressor who lost twenty-seven years of HIV-1 control
- Author
-
Ana Moyano, Oscar Blanch-Lombarte, Laura Tarancon-Diez, Nuria Pedreño-Lopez, Miguel Arenas, Tamara Alvaro, Concepción Casado, Isabel Olivares, Mar Vera, Carmen Rodriguez, Jorge del Romero, Cecilio López-Galíndez, Ezequiel Ruiz-Mateos, Julia G. Prado, and María Pernas
- Subjects
Long-term non-progressor (LTNP) ,Loss of viral control (LVC) ,Env-EL9 escape HLA-B*14:02 ,CD8 + T-cells ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Abstract Background Long-Term Non-Progressors (LTNPs) are untreated Human Immunodeficiency virus type 1 (HIV-1) infected individuals able to control disease progression for prolonged periods. However, the LTNPs status is temporary, as viral load increases followed by decreases in CD4 + T-cell counts. Control of HIV-1 infection in LTNPs viremic controllers, have been associated with effective immunodominant HIV-1 Gag-CD8 + T-cell responses restricted by protective HLA-B alleles. Individuals carrying HLA-B*14:02 control HIV-1 infection is related to an immunodominant Env-CD8 + T-cell response. Limited data are available on the contribution of HLA-B*14:02 CD8 + T -cells in LTNPs. Results In this study, we performed a virological and immunological detailed analysis of an HLA-B*14:02 LNTP individual that lost viral control (LVC) 27 years after HIV-1 diagnosis. We analysed viral evolution and immune escape in HLA-B*14:02 restricted CD8 + T -cell epitopes and identified viral evolution at the Env-EL9 epitope selecting the L592R mutation. By IFN-γ ELISpot and immune phenotype, we characterized HLA- B*14:02 HIV-1 CD8 + T cell responses targeting, Gag-DA9 and Env-EL9 epitopes before and after LVC. We observed an immunodominant response against the Env-EL9 epitope and a decreased of the CD8 T + cell response over time with LVC. Loss of Env-EL9 responses was concomitant with selecting K588R + L592R mutations at Env-EL9. Finally, we evaluated the impact of Env-EL9 escape mutations on HIV-1 infectivity and Env protein structure. The K588R + L592R escape variant was directly related to HIV-1 increase replicative capacity and stability of Env at the LVC. Conclusions These findings support the contribution of immunodominant Env-EL9 CD8 + T-cell responses and the imposition of immune escape variants with higher replicative capacity associated with LVC in this LNTP. These data highlight the importance of Env-EL9 specific-CD8 + T-cell responses restricted by the HLA-B*14:02 and brings new insights into understanding long-term HIV-1 control mediated by Env mediated CD8 + T-cell responses.
- Published
- 2022
- Full Text
- View/download PDF
5. SARS-CoV2 Infection During Pregnancy Causes Persistent Immune Abnormalities in Women Without Affecting the Newborns
- Author
-
Elena Vazquez-Alejo, Laura Tarancon-Diez, Itzíar Carrasco, Sara Vigil-Vázquez, Mar Muñoz-Chapuli, Elena Rincón-López, Jesús Saavedra-Lozano, Mar Santos-Sebastián, David Aguilera-Alonso, Alicia Hernanz-Lobo, Begoña Santiago-García, Juan Antonio de León-Luis, Patricia Muñoz, Manuel Sánchez-Luna, María Luisa Navarro, and Mª Ángeles Muñoz-Fernández
- Subjects
SARS-CoV2 ,pregnancy ,SARS-CoV2 exposed newborns ,immune system ,longitudinal analysis ,Immunologic diseases. Allergy ,RC581-607 - Abstract
SARS-CoV2 infection in pregnancy and exposed newborns is poorly known. We performed a longitudinal analysis of immune system and determined soluble cytokine levels in pregnant women infected with SARS-CoV2 and in their newborns. Women with confirmed SARS-CoV2 infection and their exposed uninfected newborns were recruited from Hospital General Universitario Gregorio Marañón. Peripheral blood mononuclear cells (PBMCs), cord cells and plasma were collected at birth and 6 months later. Immunophenotyping of natural killer (NK), monocytes and CD4/CD8 T-cells were studied in cryopreserved PBMCs and cord cells by multiparametric flow cytometry. Up to 4 soluble pro/anti-inflammatory cytokines were assessed in plasma/cord plasma by ELISA assay. SARS-CoV2-infected mothers and their newborns were compared to matched healthy non-SARS-CoV2-infected mothers and their newborns. The TNFα and IL-10 levels of infected mothers were higher at baseline than those of healthy controls. Infected mothers showed increased NK cells activation and reduced expression of maturation markers that reverted after 6 months. They also had high levels of Central Memory and low Effector Memory CD4-T cell subsets. Additionally, the increased CD4- and CD8-T cell activation (CD154 and CD38) and exhaustion (TIM3/TIGIT) levels at baseline compared to controls remained elevated after 6 months. Regarding Treg cells, the levels were lower at infected mothers at baseline but reverted after 6 months. No newborn was infected at birth. The lower levels of monocytes, NK and CD4-T cells observed at SARS-CoV2-exposed newborns compared to unexposed controls significantly increased 6 months later. In conclusion, SARS-CoV2 infection during pregnancy shows differences in immunological components that could lead newborns to future clinical implications after birth. However, SARS-CoV2 exposed 6-months-old newborns showed no immune misbalance, whereas the infected mothers maintain increased activation and exhaustion levels in T-cells after 6 months.
- Published
- 2022
- Full Text
- View/download PDF
6. Persistent Exhausted T-Cell Immunity after Severe COVID-19: 6-Month Evaluation in a Prospective Observational Study
- Author
-
Elena Vazquez-Alejo, Laura Tarancon-Diez, Maria de la Sierra Espinar-Buitrago, Miguel Genebat, Alba Calderón, Guillermo Pérez-Cabeza, Esmeralda Magro-Lopez, Manuel Leal, and Mª Ángeles Muñoz-Fernández
- Subjects
SARS-CoV-2 ,severe COVID-19 ,hospitalization ,immune exhaustion profile ,SARS-CoV-2-specific T-cell response ,long-term evolution ,Medicine - Abstract
Introduction: Severe COVID-19 can result in a significant and irreversible impact on long-term recovery and subsequent immune protection. Understanding the complex immune reactions may be useful for establishing clinically relevant monitoring. Methods: Hospitalized adults with SARS-CoV-2 between March/October 2020 (n = 64) were selected. Cryopreserved peripheral blood mononuclear cells (PBMCs) and plasma samples were obtained at hospitalization (baseline) and 6 months after recovery. Immunological components’ phenotyping and SARS-CoV-2-specific T-cell response were studied in PBMCs by flow cytometry. Up to 25 plasma pro/anti-inflammatory cytokines/chemokines were assessed by LEGENDplex immunoassays. The SARS-CoV-2 group was compared to matched healthy donors. Results: Biochemical altered parameters during infection were normalized at a follow-up time point in the SARS-CoV-2 group. Most of the cytokine/chemokine levels were increased at baseline in the SARS-CoV-2 group. This group showed increased Natural Killer cells (NK) activation and decreased CD16high NK subset, which normalized six months later. They also presented a higher intermediate and patrolling monocyte proportion at baseline. T cells showed an increased terminally differentiated (TemRA) and effector memory (EM) subsets distribution in the SARS-CoV-2 group at baseline and continued to increase six months later. Interestingly, T-cell activation (CD38) in this group decreased at the follow-up time point, contrary to exhaustion markers (TIM3/PD1). In addition, we observed the highest SARS-CoV-2-specific T-cell magnitude response in TemRA CD4 T-cell and EM CD8 T-cell subsets at the six-months time point. Conclusions: The immunological activation in the SARS-CoV-2 group during hospitalization is reversed at the follow-up time point. However, the marked exhaustion pattern remains over time. This dysregulation could constitute a risk factor for reinfection and the development of other pathologies. Additionally, high SARS-CoV-2-specific T-cells response levels appear to be associated with infection severity.
- Published
- 2023
- Full Text
- View/download PDF
7. miRNA Profile Based on ART Delay in Vertically Infected HIV-1 Youths Is Associated With Inflammatory Biomarkers and Activation and Maturation Immune Levels
- Author
-
Laura Tarancon-Diez, Irene Consuegra, Elena Vazquez-Alejo, Ricardo Ramos-Ruiz, José Tomás Ramos, María Luisa Navarro, and Mª Ángeles Muñoz-Fernández
- Subjects
miRNA profile ,vertically acquired-HIV-1 infection ,ART ,youths ,inflammatory profile ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Early antiretroviral treatment (ART) in vertically acquired HIV-1-infection is associated with a rapid viral suppression, small HIV-1 reservoir, reduced morbimortality and preserved immune functions. We investigated the miRNA profile from vertically acquired HIV-1-infected young adults based on ART initiation delay and its association with the immune system activation. Using a microRNA panel and multiparametric flow cytometry, miRNome profile obtained from peripheral blood mononuclear cells and its association with adaptive and innate immune components were studied on vertically HIV-1-infected young adults who started ART early (EARLY, 0-53 weeks after birth) and later (LATE, 120-300 weeks). miR-1248 and miR-155-5p, were significantly upregulated in EARLY group compared with LATE group, while miR-501-3p, miR-548d-5p, miR-18a-3p and miR-296-5p were significantly downregulated in EARLY treated group of patients. Strong correlations were obtained between miRNAs levels and soluble biochemical biomarkers and immunological parameters including CD4 T-cell count and maturation by CD69 expression on CD4 T-cells and activation by HLA-DR on CD16high NK cell subsets for miR-1248 and miR-155-5p. In this preliminary study, a distinct miRNA signature discriminates early treated HIV-1-infected young adults. The role of those miRNAs target genes in the modulation of HIV-1 replication and latency may reveal new host signaling pathways that could be manipulated in antiviral strategies. Correlations between miRNAs levels and inflammatory and immunological markers highlight those miRNAs as potential biomarkers for immune inflammation and activation in HIV-1-infected young adults who initiated a late ART.
- Published
- 2022
- Full Text
- View/download PDF
8. Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure
- Author
-
Concepcion Casado, Cristina Galvez, Maria Pernas, Laura Tarancon-Diez, Carmen Rodriguez, Víctor Sanchez-Merino, Mar Vera, Isabel Olivares, Rebeca De Pablo-Bernal, Alberto Merino-Mansilla, Jorge Del Romero, Ramon Lorenzo-Redondo, Ezequiel Ruiz-Mateos, María Salgado, Javier Martinez-Picado, and Cecilio Lopez-Galindez
- Subjects
Medicine ,Science - Abstract
Abstract Elite controllers (EC) represent a small subset of HIV-1-infected people that spontaneously control viral replication. However, natural virological suppression and absence of immune dysfunction are not always long-term sustained. We define exceptional EC (EEC) as HIV-1 subjects who maintain the EC characteristics without disease progression for more than 25 years. We analyzed three EEC, diagnosed between 1988 and 1992, who never showed signs of clinical disease progression in absence of any antiretroviral treatment. A comprehensive clinical, virological, and immunological study was performed. The individuals simultaneously exhibited ≥3 described host protective alleles, low levels of total HIV-1 DNA (0.50). Inflammation levels of EEC were similar to HIV-1 negative donors. Remarkably, they showed an exceptional lack of viral evolution and 8-fold lower genetic diversity (
- Published
- 2020
- Full Text
- View/download PDF
9. Threshold Ferritin Concentrations Reflecting Early Iron Deficiency Based on Hepcidin and Soluble Transferrin Receptor Serum Levels in Patients with Absolute Iron Deficiency
- Author
-
Laura Tarancon-Diez, Miguel Genebat, Manuela Roman-Enry, Elena Vázquez-Alejo, Maria de la Sierra Espinar-Buitrago, Manuel Leal, and Mª Ángeles Muñoz-Fernandez
- Subjects
ferritin ,iron deficiency ,hepcidin ,soluble transferrin receptor ,Nutrition. Foods and food supply ,TX341-641 - Abstract
(1) Background: The serum ferritin cut-off to define absolute iron deficiency is not well-established. The aim of the present study was to determine a clinically relevant ferritin threshold by using early serum biomarkers of iron deficiency such as hepcidin and the soluble transferrin receptor; (2) Methods: Two hundred and twenty-eight asymptomatic subjects attending a hospital as outpatients between 1st April 2020 and 27th February 2022 were selected. Iron metabolism parameters as part of the blood analysis were requested by their doctor and included in the study. Then, they were classified into groups according to their ferritin levels and iron-related biomarkers in serum were determined, quantified, and compared between ferritin score groups and anemic subjects. (3) Results: Serum ferritin levels below 50 ng/mL establish the point from which the serum biomarker, the soluble transferrin receptor to hepcidin ratio (sTfR/Hep ratio), begins to correlate significantly with ferritin levels. (4) Conclusion: Ferritin levels ≤ 50 ng/mL are indicative of early iron deficiency; hence, this should be considered as a clinically relevant cut-off for iron deficiency.
- Published
- 2022
- Full Text
- View/download PDF
10. Immunometabolism is a key factor for the persistent spontaneous elite control of HIV-1 infectionResearch in context
- Author
-
Laura Tarancon-Diez, Esther Rodríguez-Gallego, Anna Rull, Joaquim Peraire, Consuelo Viladés, Irene Portilla, María Reyes Jimenez-Leon, Verónica Alba, Pol Herrero, Manuel Leal, Ezequiel Ruiz-Mateos, and Francesc Vidal
- Subjects
Medicine ,Medicine (General) ,R5-920 - Abstract
Background: Approximately 25% of elite controllers (ECs) lose their virological control by mechanisms that are only partially known. Recently, immunovirological and proteomic factors have been associated to the loss of spontaneous control. Our aim was to perform a metabolomic approach to identify the underlying mechanistic pathways and potential biomarkers associated with this loss of control. Methods: Plasma samples from EC who spontaneously lost virological control (Transient Controllers, TC, n = 8), at two and one year before the loss of control, were compared with a control group of EC who persistently maintained virological control during the same follow-up period (Persistent Controllers, PC, n = 8). The determination of metabolites and plasma lipids was performed by GC-qTOF and LC-qTOF using targeted and untargeted approaches. Metabolite levels were associated with the polyfunctionality of HIV-specific CD8+T-cell response. Findings: Our data suggest that, before the loss of control, TCs showed a specific circulating metabolomic profile characterized by aerobic glycolytic metabolism, deregulated mitochondrial function, oxidative stress and increased immunological activation. In addition, CD8+ T-cell polyfunctionality was strongly associated with metabolite levels. Finally, valine was the main differentiating factor between TCs and PCs. Interpretation: All these metabolomic differences should be considered not only as potential biomarkers but also as therapeutic targets in HIV infection. Fund: This work was supported by grants from Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Fondos FEDER; Red de Investigación en Sida, Gilead Fellowship program, Spanish Ministry of Education and Spanish Ministry of Economy and Competitiveness. Keywords: Elite controllers, Energy metabolism, HIV-1, Immunometabolism, Loss of control, Metabolomic profile
- Published
- 2019
- Full Text
- View/download PDF
11. Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance—Supercontrollers
- Author
-
Beatriz Dominguez-Molina, Sara Ferrando-Martinez, Laura Tarancon-Diez, Jose Hernandez-Quero, Miguel Genebat, Francisco Vidal, Mª Angeles Muñoz-Fernandez, Manuel Leal, Richard Koup, and Ezequiel Ruiz-Mateos
- Subjects
HIV ,controllers ,HCV ,spontaneous clearance ,T-cells ,pDCs ,Immunologic diseases. Allergy ,RC581-607 - Abstract
HIV-elite controllers are a minority group of HIV-infected patients with the ability to maintain undetectable HIV viremia for long time periods without antiretroviral treatment. A small group of HIV-controllers are also able to spontaneously clear the hepatitis C virus (HCV) whom we can refer to as “supercontrollers.” There are no studies that explore immune correlates looking for the mechanisms implicated in this extraordinary phenomenon. Herein, we have analyzed HCV- and HIV-specific T-cell responses, as well as T, dendritic and NK cell phenotypes. The higher HCV-specific CD4 T-cell polyfunctionality, together with a low activation and exhaustion T-cell phenotype was found in supercontrollers. In addition, the frequency of CD8 CD161high T-cells was related with HIV- and HCV-specific T-cells polyfunctionality. Interesting features regarding NK and plasmacytoid dendritic cells (pDCs) were found. The study of the supercontroller's immune response, subjects that spontaneously controls both chronic viral infections, could provide further insights into virus-specific responses needed to develop immunotherapeutic strategies in the setting of HIV cure or HCV vaccination.
- Published
- 2018
- Full Text
- View/download PDF
12. Long-term Persistent Elite HIV-controllers: The Right Model of Functional Cure
- Author
-
Laura Tarancon-Diez, Beatriz Dominguez-Molina, Pompeyo Viciana, Luis Lopez-Cortes, and Ezequiel Ruiz-Mateos
- Subjects
Medicine ,Medicine (General) ,R5-920 - Published
- 2018
- Full Text
- View/download PDF
13. Transient Viral Rebound in Children with Perinatally Acquired HIV-1 Induces a Unique Soluble Immunometabolic Signature Associated with Decreased CD4/CD8 Ratio
- Author
-
Laura Tarancon-Diez, Joaquim Peraire, Santiago Jiménez de Ory, Maria Guirro, Luis Escosa, Luis Manuel Prieto Tato, María Penín Antón, Ana Isabel Piqueras, Álvaro Vázquez Pérez, César Gavilán, Matilde Bustillo-Alonso, María Luisa Navarro, Consuelo Viladés, Francesc Vidal, Anna Rull, and María Ángeles Muñoz-Fernández
- Subjects
Infectious Diseases ,Pediatrics, Perinatology and Child Health ,General Medicine - Abstract
Background To determine by multi-omic analysis changes in metabolites, lipids, and proteins as a consequence of transient viral rebound (tVR) in children with perinatally acquired HIV-1 (PHIV). Methods Plasma samples from children with PHIV and with tVR (first episode of transient RNA-HIV viral load >20 copies/ml followed by suppression) on the time-point immediately before (pre-tVR) and after (post-tVR) the tVR were assessed. Multi-omic analyses were performed using nLC-Orbitrap, GC-qTOF-MS, and LC-qTOF-MS. Results Comparing pre- and post-tVR time-points, HIV-1 children with tVR (n = 5) showed a trend to a decrease in ratio CD4/CD8 (p = 0.08) but no significant differences were observed in plasma metabolites, lipids, or proteins. Post-tVR condition was compared with a reference group of children with PHIV with persistent viral control (n = 9), paired by sex, age, and time under antiretroviral treatment. A total of 10 proteins, 8 metabolites, and 2 lipids showed significant differences (p < 0.05): serotransferrin, clusterin, kininogen-1, succinic acid, threonine, 2-hydroxyisovaleric acid, methionine, 2-hydroxyglutaric, triacylglyceride 50:0 (TG50:0), and diacylglyceride 34:1 (DG34:1) were upregulated while alpha-2-macroglobulin, apolipoprotein A-II, carboxylic ester hydrolase, apolipoprotein D, coagulation factor IX, peptidase inhibitor 16, SAA2-SAA4 readthrough, oleic acid, palmitoleic acid, and D-sucrose downregulated on post-tVR time-point compared to the reference group. Ratio CD4/CD8 correlated with apolipoprotein A-II, DG34:1, and methionine (p = 0.004; ρ = 0.71, p = 0.016; ρ = −0.63; and p = 0.032; ρ = −0.57, respectively). Nadir CD4+ correlated inversely with kininogen-1 (p = 0.022; ρ = −0.60) and positively with D-sucrose (p = 0.001; ρ = 0.77). Conclusions tVR followed by suppression implies changes in soluble proteins, lipids, and metabolites that correlate with immunological parameters, mainly ratio CD4/CD8, that decreased after tVR. These distinct soluble biomarkers could be considered potential biomarkers of immune progression.
- Published
- 2023
14. Early antiretroviral therapy initiation effect on metabolic profile in vertically HIV-1-infected children
- Author
-
Ma Ángeles Muñoz-Fernández, Joaquim Peraire, Elena Vazquez-Alejo, Anna Rull, Francesc Vidal, Consuelo Viladés, Laura Tarancon-Diez, Sara Guillén, Maria Luisa Navarro-Gomez, and Pol Herrero
- Subjects
Proteomics ,Microbiology (medical) ,Cart ,Population ,Human immunodeficiency virus (HIV) ,Physiology ,HIV Infections ,medicine.disease_cause ,Proinflammatory cytokine ,Metabolomics ,Antiretroviral Therapy, Highly Active ,HIV Seropositivity ,Lipidomics ,Humans ,Medicine ,Pharmacology (medical) ,Child ,education ,Pharmacology ,education.field_of_study ,business.industry ,Antiretroviral therapy ,Infectious Diseases ,HIV-1 ,Metabolome ,business ,Metabolic profile - Abstract
Background Early combined antiretroviral treatment (cART) in perinatally acquired HIV-1 children has been associated with a rapid viral suppression, small HIV-1 reservoir size and reduced mortality and morbidity. Immunometabolism has emerged as an important field in HIV-1 infection offering both relevant knowledge regarding immunopathogenesis and potential targets for therapies against HIV-1. Objectives To characterize the proteomic, lipidomic and metabolomic profile of HIV-1-infected children depending on their age at cART initiation. Patients and methods Plasma samples from perinatally HIV-1-infected children under suppressive cART who initiated an early cART (first 12 weeks after birth, EARLY, n = 10) and late cART (12–50 weeks after birth, LATE, n = 10) were analysed. Comparative plasma proteomics, lipidomics and metabolomics analyses were performed by nanoLC-Orbitrap, UHPLC-qTOF and GC-qTOF, respectively. Results Seven of the 188 proteins identified exhibited differences comparing EARLY and LATE groups of HIV-1-infected children. Despite no differences in the lipidomic (n = 115) and metabolomic (n = 81) profiles, strong correlations were found between proteins and lipid levels as well as metabolites, including glucidic components and amino acids, with clinical parameters. The ratio among different proteins showed high discriminatory power of EARLY and LATE groups. Conclusions Protein signature show a different proinflammatory state associated with a late cART introduction. Its associations with lipid levels and the relationships found between metabolites and clinical parameters may potentially trigger premature non-AIDS events in this HIV-1 population, including atherosclerotic diseases and metabolic disorders. Antiretroviral treatment should be started as soon as possible in perinatally acquired HIV-1-infected children to prevent them from future long-life complications.
- Published
- 2021
15. TLR Agonists Enhance HIV-Specific T-Cell Response Mediated by Plasmacytoid Dendritic Cells in Diverse HIV-1 Disease Progression Phenotypes
- Author
-
Maria Reyes Jimenez-Leon, Carmen Gasca-Capote, Laura Tarancon-Diez, Beatriz Dominguez-Molina, Macarena Lopez-Verdugo, Ryan Ritraj, Ana Isabel Alvarez-Rios, Joana Vitallé, Sara Bachiller, Alberto Pérez-Gómez, Nuria Espinosa, Cristina Roca-Oporto, Mohamed Rafii-El-Idrissi Benhnia, Alicia Gutierrez-Valencia, Luis Fernando López-Cortés, and Ezequiel Ruiz-Mateos
- Abstract
Plasmacytoid dendritic cells (pDCs) sense microbial products through TLR-7 and -9 and translate this sensing in Interferon-α (IFN-α) production and T-cell polarization. The understanding of the mechanisms involved in pDCs stimulation may contribute to immunotherapeutic strategies aiming to decrease HIV-1 reservoir. Here, we characterize the immunomodulatory effects of TLR agonist stimulations through a pDC/T-cell coculture in different HIV-1 disease progression phenotypes and healthy donors (HD). pDCs were previously stimulated with AT-2-HIV-1, CpGA, CpGC and GS9620. After coculture with autologous CD4 or CD8 T-cells we observed an increase of pDCs activation markers levels, interferon related genes, HIV-1 restriction factors and cytokines levels. This pDCs coordinate activation was prominent with CpGC and GS9620 and induced an increase of HIV-specific T-cell response. These results shed light on the mechanisms associated with TLR-specific pDCs stimulation associated with T cell polarization for eliciting antiviral response which is essential for HIV eradication strategies.
- Published
- 2022
16. Toll-like Receptor Agonists Enhance HIV-specific T Cell Response Mediated by Plasmacytoid Dendritic Cells in Diverse HIV-1 Disease Progression Phenotypes
- Author
-
Ezequiel Ruiz-Mateos, Maria Reyes Jimenez-Leon, Carmen Gasca-Capote, Laura Tarancon-Diez, Beatriz Dominguez-Molina, Macarena Lopez-Verdugo, Ryan Ritraj, Ana Isabel Alvarez-Rios, Joana Vitallé, Sara Bachiller, Alberto Pérez-Gómez, Nuria Espinosa, Cristina Roca-Oporto, Mohamed Rafii-El-Idrissi Benhnia, Alicia Gutierrez-Valencia, and Luis Fernando López-Cortés
- Abstract
Plasmacytoid dendritic cells (pDCs) sense viral and bacterial products through Toll-like receptor (TLR)-7 and -9 and translate this sensing in Interferon-α (IFN-α) production and T cell polarization. These cells are considered a link between innate and adaptive immunity, inducing and maintaining antigen-specific T cell responses and contributing to the control and eventually to the chronic immune activation and disease progression in HIV-1 infection scenario. The understanding of the mechanisms involved in pDCs stimulation may contribute to immunotherapeutic strategies aiming to decrease HIV-1 reservoir. The objective of the present study was to characterize the immunomodulatory effects of TLR agonist stimulations through a pDC/T cell coculture in different HIV-1 disease progression phenotypes and healthy donors (HD). pDCs were previously stimulated with AT-2-HIV-1, CpGA, CpGC and GS9620. After coculture with autologous CD4 or CD8 T cells we observed an increase of pDCs activation markers levels, interferon related genes, HIV-1 restriction factors and cytokines levels. This pDCs coordinate activation was prominent with CpG-C and GS9620 and induced an increase of HIV-specific T cell response. This pDCs dependent HIV-1 specific T-cell response was associated with the upregulation of HIV-1 restriction factors and IFN-α production. Interestingly, pDCs activation in people on ART was similar to that found in people that spontaneously control the virus. These results shed light on the mechanisms associated with TLR-specific pDCs stimulation associated with T cell polarization for eliciting antiviral response which is essential for HIV eradication strategies.
- Published
- 2022
17. Immunoescape of HIV-1 in Env-EL9 CD8+T cell response restricted by HLA-B*14:02 in a Non progressor who lost twenty-seven years of HIV-1 control
- Author
-
Ana Moyano, Oscar Blanch-Lombarte, Laura Tarancon-Diez, Nuria Pedreño-Lopez, Miguel Arenas, Tamara Alvaro, Concepción Casado, Isabel Olivares, Mar Vera, Carmen Rodriguez, Jorge del Romero, Cecilio López-Galíndez, Ezequiel Ruiz-Mateos, Julia G. Prado, María Pernas, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, European Commission, Generalitat de Catalunya, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Xunta de Galicia, Consejo Superior de Investigaciones Científicas (España), Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF), Unión Europea. Fondo Social Europeo (ESF/FSE), Agency for Administration of University and Research, Government of Catalonia (España), Government of Spain, Xunta de Galicia (España), and Redes Temáticas de Investigación Cooperativa en Salud (España)
- Subjects
Loss of viral control (LVC) ,CD8 + T-cells ,HIV Infections ,CD8-Positive T-Lymphocytes ,Viral Load ,CD8+T-cells ,Env-EL9 escape HLA-B*14 ,Infectious Diseases ,Long-term non-progressor (LTNP) ,HLA-B Antigens ,Virology ,Env-EL9 escape HLA-B*14:02 ,HIV-1 ,Humans ,02 [Env-EL9 escape HLA-B*14] ,Immune Evasion - Abstract
[Background] Long-Term Non-Progressors (LTNPs) are untreated Human Immunodeficiency virus type 1 (HIV-1) infected individuals able to control disease progression for prolonged periods. However, the LTNPs status is temporary, as viral load increases followed by decreases in CD4 + T-cell counts. Control of HIV-1 infection in LTNPs viremic controllers, have been associated with effective immunodominant HIV-1 Gag-CD8 + T-cell responses restricted by protective HLA-B alleles. Individuals carrying HLA-B*14:02 control HIV-1 infection is related to an immunodominant Env-CD8 + T-cell response. Limited data are available on the contribution of HLA-B*14:02 CD8 + T -cells in LTNPs., [Results] In this study, we performed a virological and immunological detailed analysis of an HLA-B*14:02 LNTP individual that lost viral control (LVC) 27 years after HIV-1 diagnosis. We analysed viral evolution and immune escape in HLA-B*14:02 restricted CD8 + T -cell epitopes and identified viral evolution at the Env-EL9 epitope selecting the L592R mutation. By IFN-γ ELISpot and immune phenotype, we characterized HLA- B*14:02 HIV-1 CD8 + T cell responses targeting, Gag-DA9 and Env-EL9 epitopes before and after LVC. We observed an immunodominant response against the Env-EL9 epitope and a decreased of the CD8 T + cell response over time with LVC. Loss of Env-EL9 responses was concomitant with selecting K588R + L592R mutations at Env-EL9. Finally, we evaluated the impact of Env-EL9 escape mutations on HIV-1 infectivity and Env protein structure. The K588R + L592R escape variant was directly related to HIV-1 increase replicative capacity and stability of Env at the LVC., [Conclusions] These findings support the contribution of immunodominant Env-EL9 CD8 + T-cell responses and the imposition of immune escape variants with higher replicative capacity associated with LVC in this LNTP. These data highlight the importance of Env-EL9 specific-CD8 + T-cell responses restricted by the HLA-B*14:02 and brings new insights into understanding long-term HIV-1 control mediated by Env mediated CD8 + T-cell responses., Molecular Virology Laboratory was supported by grants SAF (2016-77894-R) from Ministerio de Economía y Competitividad (MINECO), ISCIII through the projects PI 13/02269, PI17/00164, PI16/0684, PI19/01127 (Co-funded by European Regional Development Fund/European Social Fund "Investing in your future"). The RIS-RETIC grants RD12/0017/0028, RD16/0025/0020 and RD16CIII/0002/0005. LTD was supported by the Instituto de Salud Carlos III (ISCIII) under grant agreement “CD20/00025” through the Sara Borrell Program. O.B.L was funded by an AGAUR-FI_B 00582 Ph.D. fellowship from the Catalan Government and the European Social Fund. M.A. was funded by grants RYC-2015-18241 and PID2019-107931GA-I00 from the Spanish Government and, ED431F 2018/08 from the “Xunta de Galicia”. ERM was supported by the Spanish National Research Council (CSIC). JGP laboratory was supported by National Health Institute Carlos III grant PI17/00164 and Redes Temáticas de Investigación en SIDA (ISCIII RETIC RD16/0025/0041).
- Published
- 2022
18. CD300a identifies a CD4+ memory T cell subset with a higher susceptibility to HIV-1 infection
- Author
-
María Reyes Jimenez-Leon, Francisco Borrego, Luis F. López-Cortés, Ezequiel Ruiz-Mateos, Ane Orrantia, Laura Tarancon-Diez, Cristina Roca-Oporto, Joana Vitallé, Iñigo Terrén, and Olatz Zenarruzabeitia
- Subjects
CD4-Positive T-Lymphocytes ,0301 basic medicine ,Immunology ,Human immunodeficiency virus (HIV) ,HIV Infections ,Biology ,medicine.disease_cause ,Dengue fever ,03 medical and health sciences ,0302 clinical medicine ,Viral envelope ,Antigens, CD ,medicine ,Humans ,Immunology and Allergy ,030212 general & internal medicine ,Receptors, Immunologic ,CD4+ Memory T Cell ,medicine.disease ,Virology ,In vitro ,030104 developmental biology ,Infectious Diseases ,HIV-1 ,Biomarker (medicine) ,Immunologic Memory - Abstract
Human CD300a is known to promote the infection by dengue and other enveloped viruses and is overexpressed on CD4+ T cells from HIV-1-infected patients. We found that infected CD4+RA− T cells from untreated HIV-1-infected patients were mostly CD300a+. Furthermore, CD300a expressing CD4+RA− T cells from healthy donors were significantly more infected by HIV-1 in vitro than CD300a− cells. CD300a might represent a biomarker of susceptibility to HIV-1 infection on memory CD4+ T lymphocytes.
- Published
- 2020
19. Innate and adaptive abnormalities in youth with vertically acquired HIV through a multicentre cohort in Spain
- Author
-
Angielys Zamora, María Luisa Navarro, Cristina Epalza, Talía Sainz, José Antonio Iribarren, María Ángeles Muñoz-Fernández, Miren Apilanez, Laura Tarancon-Diez, Santiago Jiménez de Ory, Jose I Bernardino, Itzíar Carrasco, Sara Guillén, Cristina Diez, Elena Vazquez-Alejo, and José Tomás Ramos
- Subjects
Senescence ,Adult ,CD4-Positive T-Lymphocytes ,antiretroviral treatment (ART) ,Adolescent ,Receptor expression ,HIV Infections ,CD8-Positive T-Lymphocytes ,Lymphocyte Activation ,Young Adult ,Immune system ,TIGIT ,exhaustion ,Medicine ,Humans ,Interleukin-7 receptor ,Research Articles ,immunosenescence ,business.industry ,Public Health, Environmental and Occupational Health ,HIV ,Immunosenescence ,NKG2D ,Infectious Diseases ,Anti-Retroviral Agents ,Spain ,Immunology ,Leukocytes, Mononuclear ,activation ,vertical transmission ,business ,CD8 ,Research Article - Abstract
Introduction Immune abnormalities have been described among youth with vertically acquired HIV (YWVH) despite antiretroviral treatment (ART). The CD4/CD8 ratio could be a useful prognostic marker. We assess immune activation and senescence in a cohort of YWVH in comparison to youth without vertically acquired HIV. Methods YWVH under suppressive ART were included and compared to a group of HIV‐negative donors (HD) matched by age and sex, from September 2019 to September 2020. Subset distribution and expression of activation, maturation, senescence and exhaustion markers on T and NK cells were studied on peripheral blood mononuclear cells by multiparametric flow cytometry. Results Thirty‐two YWVH (median age: 24.4 years (interquartile range: 22.5 to 28.3 years)) were included. Among YWVH, CD4‐ and CD8‐T cells showed high levels of activation (HLA‐DR/CD38), IL‐7 receptor expression (CD127) and exhaustion (TIM‐3). Regarding NK cells, YWVH showed increased levels of activation and exhaustion markers compared to HD. Strong inverted correlations were observed between T‐cell activation (HLA‐DR/CD38), senescence (CD57) and exhaustion (TIGIT, PD‐1) levels with the CD4/CD8 ratio among YWVH. HLA‐DR, CD69, NKG2D and NKG2A expression levels on NK cells also correlated with the CD4/CD8 ratio. Age at ART initiation was directly associated with higher frequency of CD16high NK‐cell subsets, exhaustion T‐cell levels (CD57, TIM3) and NK cells activation levels. Conclusions Immunological changes associated with vertically acquired HIV, characterized by increased activation and exhaustion levels in innate and adaptive immune components, are only partially restored by ART. The CD4/CD8 ratio can be a useful marker of disease progression for routine clinical practice.
- Published
- 2021
20. Caecum OX40+CD4 T-cell subset associates with mucosal damage and key markers of disease in treated HIV-infection
- Author
-
Isaac Rosado-Sánchez, Inés Herrero-Fernández, Salvador Sobrino, Ana E. Carvajal, Miguel Genebat, Laura Tarancón-Díez, María Carmen Garcia-Guerrero, María Carmen Puertas, Rocío M. de Pablos, Rocío Ruiz, Javier Martinez-Picado, Manuel Leal, and Yolanda M. Pacheco
- Subjects
Caecum ,HIV ,OX40 ,Thymus ,GALT ,Microbiology ,QR1-502 - Abstract
Background: Blood OX40-expressing CD4 T-cells from antiretroviral (ART)-treated people living with HIV (PWH) were found to be enriched for clonally-expanded HIV sequences, hence contributing to the HIV reservoir. OX40-OX40L is also a checkpoint regulator of inflammation in multiple diseases. We explored gut mucosal OX40+CD4+ T-cells and their potential significance in HIV disease. Methods: Biopsies of caecum and terminal-ileum of ART-treated PWH (n = 32) were obtained and mucosal damage and HIV reservoir were assessed. Mucosal OX40+ and Ki67+ CD4 T-cell subsets, as well as several tissue T-cell subsets modulating mucosal integrity and homeostasis (Th17, Th22, Treg, Tc17, Tc22, IL17+TCRγδ, IL22+TCRγδ) were quantified. Inflammatory-related markers, T-cell activation and thymic output were also determined in blood samples. Correlations were explored using Spearman rank test and corrected for multiple comparisons by Benjamini-Hochberg. Results: Compared to healthy controls, a high frequency of mucosal, mainly caecum, CD4 T-cells were OX40+ in PWH. Such frequency strongly correlated with nadir CD4 (r = −0.836; p
- Published
- 2023
- Full Text
- View/download PDF
21. Modulation of Monocyte Activation and Function during Direct Antiviral Agent Treatment in Patients Coinfected with HIV and Hepatitis C Virus
- Author
-
Yusnelkis Milanés-Guisado, Maria Trujillo-Rodriguez, Ana I. Alvarez-Rios, Luis F. López-Cortés, Alicia Gutierrez-Valencia, M. Reyes Jimenez-Leon, Ezequiel Ruiz-Mateos, Pompeyo Viciana, Nuria Espinosa, Cristina Roca-Oporto, Rebeca S. de Pablo-Bernal, Ana Serna-Gallego, Laura Tarancon-Diez, Instituto de Salud Carlos III, Red Española de Investigación en SIDA, European Commission, and Junta de Andalucía
- Subjects
Lipopolysaccharide ,cell-associated DNA ,Cell-associated DNA: Inflammation ,HIV Infections ,Hepacivirus ,CD49d ,medicine.disease_cause ,Monocytes ,chemistry.chemical_compound ,0302 clinical medicine ,CX3CR1 ,Pharmacology (medical) ,0303 health sciences ,biology ,medicine.diagnostic_test ,Coinfection ,virus diseases ,Hepatitis C ,Infectious Diseases ,medicine.anatomical_structure ,polyfunctionality ,monocyte ,HCV ,030211 gastroenterology & hepatology ,Tumor necrosis factor alpha ,Hepatitis C virus ,Activation ,Antiviral Agents ,Flow cytometry ,03 medical and health sciences ,medicine ,Humans ,030304 developmental biology ,Reservoir ,Pharmacology ,CD40 ,business.industry ,Monocyte ,HIV ,DAAs ,Hepatitis C, Chronic ,Monocyte: Polyfunctionality ,chemistry ,inflammation ,Polyfunctionality [Monocyte] ,Immunology ,biology.protein ,Inflammation [Cell-associated DNA] ,business - Abstract
The activation phenotypes and functional changes in monocyte subsets during hepatitis C virus (HCV) elimination in HIV/HCV-coinfected patients were evaluated. Twenty-two HIV/HCV-coinfected patients on suppressive combination antiretroviral treatment (cART) achieving HCV elimination after direct-acting antiviral (DAA) therapy and 10 HIV-monoinfected patients were included. The activation phenotype (10 markers) and polyfunctionality (intracellular interleukin-1α [IL-1α], IL-1β, IL-6, IL-8, tumor necrosis factor alpha [TNF-α], and IL-10 production) in three monocyte subsets (classical, intermediate, and nonclassical) were evaluated by flow cytometry before and at the end of treatment. Cell-associated HIV DNA levels were assayed by droplet digital PCR. After HCV clearance, there was a significant increase in classical monocyte and decreases in intermediate and nonclassical monocyte levels. The levels of the activation markers CD49d, CD40, and CX3CR1 were decreased after treatment in the monocyte subsets, reaching the levels in HIV-monoinfected patients. After lipopolysaccharide (LPS) stimulation, although polyfunctionality significantly decreased in intermediate and nonclassical monocytes, some combinations, such as the IL-1α− (IL-1α-negative) IL-1β− IL-6+ (IL-6-producing) IL-8− TNF-α− IL-10− combination, were remarkably increased at the end of treatment compared to the control group. Cell-associated HIV DNA levels correlated with activation markers before but not after treatment. HCV clearance after DAA treatment in patients on cART exerts an anti-inflammatory profile on monocyte subsets, activation phenotypes, and polyfunctionality. However, there is not a complete normalization compared with HIV-monoinfected patients., This work was supported by the Instituto de Salud Carlos III (research contracts CPII014/00025 to E.R.-M., CP19/00159 to A.G.-V., FI17/00186 to M.R.J.-L., and FI14/00431 to L.T.-D. and research projects PI16/00684 and PI19/01127 to E.R.-M.) and the Red Temática de Investigación Cooperativa en SIDA (RD16/0025/0020 and RD16/0025/0019), which is included in the Acción Estratégica en Salud, Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica, 2008 to 2011 and 2013 to 2016, Instituto de Salud Carlos III, Fondos FEDER. E.R.-M. was supported by the Consejería de Salud y Bienestar Social of the Junta de Andalucía through the Nicolás Monardes program (C-0032/17).
- Published
- 2020
22. Coronavirus Disease (COVID-19): A Perspective from Immunosenescence
- Author
-
Miguel Genebat, Laura Tarancon-Diez, Alba Calderón, Ma Ángeles Muñoz-Fernández, Rebeca S. de Pablo-Bernal, and Manuel Leal
- Subjects
2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Perspective (graphical) ,Cell Biology ,Disease ,Immunosenescence ,medicine.disease_cause ,Virology ,Pathology and Forensic Medicine ,Medicine ,Neurology (clinical) ,Geriatrics and Gerontology ,business ,Letter to the Editor ,Coronavirus - Published
- 2020
23. Polyfunctional HIV-1 specific response by CD8+ T lymphocytes expressing high levels of CD300a
- Author
-
Francisco Borrego, Miguel Genebat, Ane Orrantia, Ezequiel Ruiz-Mateos, Manuel Leal, Joana Vitallé, Leire Gamboa-Urquijo, Laura Tarancon-Diez, Iñigo Terrén, Olatz Zenarruzabeitia, [Vitallé,J, Terrén,I, Gamboa-Urquijo,L, Orrantia,A, Borrego,F, Zenarruzabeitia,O] Biocruces Bizkaia Health Research Institute, Immunopathology Group, Barakaldo, Spain. [Tarancón-Díez,L, Genebat,M, Leal,M, Ruiz-Mateos,E] Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital, University of Seville, CSIC, Seville, Spain. [Tarancón-Díez,L] Laboratory of Molecular Immuno-Biology, Gregorio Marañón University Hospital, Health Research Institute, Madrid, Spain. [Leal,M] Internal Medicine Service, Santa Ángela de la Cruz Viamed Hospital, Sevilla, Spain. [Borrego,F] Ikerbasque, Basque Foundation for Science, Bilbao, Spain., This study was supported by a grant from 'Plan Estatal de I+ D+ I 2013–2016, ISCIII-Subdirección de Evaluación y Fomento de la Investigación-Fondo Europeo de Desarrollo Regional (FEDER) (Grant PI13/00889)' and Marie Curie Actions, Career Integration Grant, European Commission (Grant CIG 631674). Joana Vitallé and Iñigo Terrén are recipients of a predoctoral contract funded by the Department of Education, Basque Government (PRE_2017_2_0242 and PRE_2018_1_0032). Joana Vitallé and Iñigo Terrén are recipients of a fellowship from the Jesús de Gangoiti Barrera Foundation (FJGB15/008 and FJGB17/003). Laura Tarancón-Díez was supported by Instituto de Salud Carlos III, PFIS (FI00/00431). Olatz Zenarruzabeitia is recipient of a postdoctoral contract funded by 'Instituto de Salud Carlos III-Contratos Sara Borrell 2017 (CD17/0128)' and the European Social Fund (ESF)-The ESF invests in your future. Ezequiel Ruiz-Mateos is supported by Programa Nicolás Monardes, C0032-2017, Consejería de Salud y Bienestar Social, Junta de Andalucía. Francisco Borrego is an Ikerbasque Research Professor, Ikerbasque, Basque Foundation for Science., Instituto de Salud Carlos III, European Commission, Eusko Jaurlaritza, Fundación Jesús de Gangoiti Barrera, Junta de Andalucía, and Ikerbasque Basque Foundation for Science
- Subjects
0301 basic medicine ,Receptor expression ,medicine.medical_treatment ,T-Lymphocytes ,lcsh:Medicine ,HIV Infections ,CD8-Positive T-Lymphocytes ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,0302 clinical medicine ,Cytotoxic T cell ,Receptors, Immunologic ,Receptor ,lcsh:Science ,Cells, Cultured ,Multidisciplinary ,medicine.diagnostic_test ,CD300a receptor ,Degranulation ,virus diseases ,Citocinas ,Linfocitos T ,3. Good health ,Cytokine ,medicine.anatomical_structure ,Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents::Anti-HIV Agents [Medical Subject Headings] ,030220 oncology & carcinogenesis ,Cytokines ,Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections [Medical Subject Headings] ,Cell biology ,Anti-HIV Agents ,T cell ,Immunology ,Biology ,Article ,Flow cytometry ,03 medical and health sciences ,Antigens, CD ,medicine ,Humans ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides [Medical Subject Headings] ,Organisms::Viruses::RNA Viruses::Retroviridae::Lentivirus::Lentiviruses, Primate::HIV::HIV-1 [Medical Subject Headings] ,Phenomena and Processes::Chemical Phenomena::Biochemical Phenomena::Biochemical Processes::Up-Regulation [Medical Subject Headings] ,lcsh:R ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Intercellular Signaling Peptides and Proteins::Cytokines [Medical Subject Headings] ,Péptidos ,030104 developmental biology ,Anatomy::Cells::Cells, Cultured [Medical Subject Headings] ,HIV-1 ,lcsh:Q ,Chemicals and Drugs::Biological Factors::Antigens::Antigens, Surface::Antigens, Differentiation::Antigens, CD [Medical Subject Headings] ,Anatomy::Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::T-Lymphocytes::T-Lymphocyte Subsets [Medical Subject Headings] ,Peptides ,CD8 ,Anatomy::Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::T-Lymphocytes::CD8-Positive T-Lymphocytes [Medical Subject Headings] - Abstract
CD300a receptor is found on different CD8+ T cell subsets and its expression has been associated to a more cytotoxic molecular signature. CD300a has an important role in some viral infections and its expression levels are known to be modulated by human immunodeficiency virus (HIV)−1 infection on several cell types. The main objective of this work was to investigate CD300a expression and its regulation during HIV-1 specific CD8+ T cell responses. CD300a receptor expression was analysed by multiparametric flow cytometry on CD8+ T lymphocytes from HIV negative donors, naive HIV-1+ individuals and HIV-1+ subjects under suppressive combined antiretroviral therapy (cART). HIV-1 specific CD8+ T cell response was studied by stimulating cells with HIV-1 derived peptides or with a Gag HIV-1 peptide. Our results showed that HIV-1 specific CD8+ T cells expressing higher levels of CD300a were more polyfunctional showing an increased degranulation and cytokine production. Moreover, we observed an up-regulation of CD300a expression after Gag HIV-1 peptide stimulation. Finally, our results demonstrated an inverse correlation between CD300a expression on CD8+ T lymphocytes and HIV disease progression markers. In conclusion, CD300a expression is associated to a better and more polyfunctional HIV-1 specific CD8+ T cell response., This study was supported by a grant from “Plan Estatal de I+ D+ I 2013–2016, ISCIII-Subdirección de Evaluación y Fomento de la Investigación-Fondo Europeo de Desarrollo Regional (FEDER) (Grant PI13/00889)” and Marie Curie Actions, Career Integration Grant, European Commission (Grant CIG 631674). Joana Vitallé and Iñigo Terrén are recipients of a predoctoral contract funded by the Department of Education, Basque Government (PRE_2017_2_0242 and PRE_2018_1_0032). Joana Vitallé and Iñigo Terrén are recipients of a fellowship from the Jesús de Gangoiti Barrera Foundation (FJGB15/008 and FJGB17/003). Laura Tarancón-Díez was supported by Instituto de Salud Carlos III, PFIS (FI00/00431). Olatz Zenarruzabeitia is recipient of a postdoctoral contract funded by “Instituto de Salud Carlos III-Contratos Sara Borrell 2017 (CD17/0128)” and the European Social Fund (ESF)-The ESF invests in your future. Ezequiel Ruiz-Mateos is supported by Programa Nicolás Monardes, C0032-2017, Consejería de Salud y Bienestar Social, Junta de Andalucía. Francisco Borrego is an Ikerbasque Research Professor, Ikerbasque, Basque Foundation for Science.
- Published
- 2020
24. Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure
- Author
-
Cecilio López-Galíndez, Rebeca S. de Pablo-Bernal, Carmen Rodríguez, Isabel Olivares, Ezequiel Ruiz-Mateos, Maria Pernas, Mar Vera, Alberto Merino-Mansilla, Ramon Lorenzo-Redondo, Victor Sanchez-Merino, Maria Cristina O. Salgado, Cristina Gálvez, Concepción Casado, Javier Martinez-Picado, Laura Tarancon-Diez, Jorge del Romero, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (España), Red Española de Investigación en SIDA, European Commission, Junta de Andalucía, Grifols, Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF), Red de Investigación Cooperativa en Investigación en Sida (España), Regional Government of Andalusia (España), [Casado,C, Pernas,M, Olivares,I, Lopez-Galindez,C] Virología Molecular, Laboratorio de Referencia e Investigación en Retrovirus, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain. [Galvez,C, Salgado,M, Martinez-Picado,J] AIDS Research Institute IrsiCaixa, Badalona, Spain. [Galvez,C] Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain. [Tarancon-Diez,L, De Pablo-Bernal,R, Ruiz-Mateos,E] Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital, CSIC, University of Seville, Seville, Spain. [Rodriguez,C, Vera,M, Del Romero,J] Centro Sanitario Sandoval, Hospital Clínico San Carlos. IdISSC, Madrid, Spain. [Sanchez-Merino,V, Merino-Mansilla,A] AIDS Immunopathology Unit. Laboratorio de Referencia e Investigación en Retrovirus. Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain. [Lorenzo-Redondo,R] Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. [Martinez-Picado,J] University of Vic-Central University of Catalonia (UVic-UCC), Vic, Spain. [Martinez-Picado,J] Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain., Work in Centro Nacional de Microbiologia (ISCIII) was supported by grants SAF (2016–77894-R) from Ministerio de Economia y Competitividad (MINECO) (Spain) and Fondo de Investigación Sanitaria(FIS)-Instituto de Salud CarlosIII, grant FIS (PI 13/02269, ISCIII) and in part by the RIS-RETIC grants RD12/0017/0028 and RD16CIII/0002/0005 funded by the ISCIII-FEDER. MP has a contract of RIS-RETICRD16CIII/0002/0005. Tis work was supported by grants from the MINECO, FIS-Instituto de Salud CarlosIII, Fondos Europeos para el Desarrollo Regional, FEDER, grant numbers PI16/00684, PI19/01127, CPII014/00025 to ER-M. and FI14/00431 to LT-D., the Gilead Fellowship Program (grant numbers GLD17/00299), and the Red de Investigación en Sida (grant number RD16/0025/0020). ER-M. is supported by Consejería de Salud y BienestarSocial of Junta de Andalucía through the Nicolás Monardes Program (C-0032/17). Research in VS-M group was supported by Fondo de Investigación Sanitaria (FIS)-Instituto de Salud CarlosIII, grant FIS (PI 17CIII/00049). Grifols partially supported work in the AIDS Research Institute IrsiCaixa.
- Subjects
0301 basic medicine ,Male ,ADN ,Remission, Spontaneous ,Diseases ,HIV Infections ,Pathogenesis ,Anatomy::Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::T-Lymphocytes::CD4-Positive T-Lymphocytes [Medical Subject Headings] ,Virus Replication ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Genes, Microbial::Genes, Viral::Genes, env [Medical Subject Headings] ,Viral load ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Models, Theoretical::Models, Biological [Medical Subject Headings] ,Multidisciplinary ,Molecular medicine ,Middle Aged ,Viral Load ,Virus ,Viral evolution ,Viruses ,Spontaneous cure ,Disease Progression ,Medicine ,Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections [Medical Subject Headings] ,Female ,medicine.symptom ,VIH-1 ,Evolution ,Science ,030106 microbiology ,Check Tags::Male [Medical Subject Headings] ,Inflammation ,Models, Biological ,Article ,HIV Long-Term Survivors ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Clinical Laboratory Techniques::Microbiological Techniques::Viral Load [Medical Subject Headings] ,03 medical and health sciences ,Immune system ,Elite controllers, HIV ,Progresión de la enfermedad ,medicine ,Humans ,Allele ,Disease progression ,Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Progression [Medical Subject Headings] ,Organisms::Viruses::RNA Viruses::Retroviridae::Lentivirus::Lentiviruses, Primate::HIV::HIV-1 [Medical Subject Headings] ,Host Microbial Interactions ,business.industry ,Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings] ,DNA ,Phenomena and Processes::Immune System Phenomena::Immunity [Medical Subject Headings] ,Persons::Persons::Patients::Survivors::HIV Long-Term Survivors [Medical Subject Headings] ,Carga viral ,Phenomena and Processes::Microbiological Phenomena::Microbiological Processes::Virus Physiological Processes::Virus Replication [Medical Subject Headings] ,030104 developmental biology ,Check Tags::Female [Medical Subject Headings] ,Viral replication ,Immunology ,HIV-1 ,Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Progression::Remission, Spontaneous [Medical Subject Headings] ,VIH no-progresivos ,Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::DNA [Medical Subject Headings] ,business ,Biomarkers - Abstract
Elite controllers (EC) represent a small subset of HIV-1-infected people that spontaneously control viral replication. However, natural virological suppression and absence of immune dysfunction are not always long-term sustained. We define exceptional EC (EEC) as HIV-1 subjects who maintain the EC characteristics without disease progression for more than 25 years. We analyzed three EEC, diagnosed between 1988 and 1992, who never showed signs of clinical disease progression in absence of any antiretroviral treatment. A comprehensive clinical, virological, and immunological study was performed. The individuals simultaneously exhibited ≥3 described host protective alleles, low levels of total HIV-1 DNA (0.50). Inflammation levels of EEC were similar to HIV-1 negative donors. Remarkably, they showed an exceptional lack of viral evolution and 8-fold lower genetic diversity (, Work in Centro Nacional de Microbiologia (ISCIII) was supported by grants SAF (2016–77894-R) from Ministerio de Economia y Competitividad (MINECO) (Spain) and Fondo de Investigación Sanitaria (FIS)-Instituto de Salud CarlosIII, grant FIS (PI 13/02269, ISCIII) and in part by the RIS-RETIC grants RD12/0017/0028 and RD16CIII/0002/0005 funded by the ISCIII-FEDER. MP has a contract of RIS-RETIC RD16CIII/0002/0005. This work was supported by grants from the MINECO, FIS-Instituto de Salud CarlosIII, Fondos Europeos para el Desarrollo Regional, FEDER, grant numbers PI16/00684, PI19/01127, CPII014/00025 to ER-M. and FI14/00431 to LT-D.; the Gilead Fellowship Program (grant numbers GLD17/00299); the Red de Investigación en Sida (grant number RD16/0025/0020). ER-M. is supported by Consejería de Salud y Bienestar Social of Junta de Andalucía through the Nicolás Monardes Program (C-0032/17). Research in VS-M group was supported by Fondo de Investigación Sanitaria (FIS)-Instituto de Salud Carlos III, grant FIS (PI 17CIII/00049). Grifols partially supported work in the AIDS Research Institute IrsiCaixa.
- Published
- 2020
25. Persistent HIV-controllers are more prone to spontaneously clear HCV: a retrospective cohort study
- Author
-
Yusnelkis Milanés-Guisado, Cecilio López-Galíndez, Concepción Casado, Salvador Resino, Beatriz Dominguez-Molina, Pompeyo Viciana, Manuel Leal, Maria Pernas, Miguel Genebat, Ezequiel Ruiz-Mateos, Juan González-García, Carmen Rodríguez, Agathe León, Felipe García, Luis F. López-Cortés, Norma Rallón, Jorge del Romero, Laura Tarancon-Diez, José Miguel Benito, Instituto de Salud Carlos III, Red Temática Cooperativa de Investigación en Sida (España), Gobierno de Andalucía, Ministerio de Educación (España), Ministerio de Economía y Competitividad (España), Redes Tematicas de Investigacion Cooperativa en Salud (España), Instituto de Salud Carlos III - ISCIII, Red Española de Investigación en SIDA, Junta de Andalucía, and Ministerio de Educación, Cultura y Deporte (España)
- Subjects
Adult ,CD4-Positive T-Lymphocytes ,Male ,medicine.medical_specialty ,Multivariate analysis ,Hepatitis C virus ,HIV Infections ,Hepacivirus ,medicine.disease_cause ,Logistic regression ,HIV Long-Term Survivors ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Persistent ,030212 general & internal medicine ,Research Articles ,Retrospective Studies ,030505 public health ,biology ,Proportional hazards model ,business.industry ,Transient ,Confounding ,HIV-controllers ,Public Health, Environmental and Occupational Health ,virus diseases ,HIV ,Retrospective cohort study ,Middle Aged ,Hepatitis C ,HIV‐controllers ,Log-rank test ,HCV spontaneous clearance ,Infectious Diseases ,HCV ,HIV-1 ,biology.protein ,Female ,Antibody ,0305 other medical science ,business ,Research Article - Abstract
ECRIS integrated in the Spanish AIDS Research Network., [Introduction] HIV‐controllers have the ability to spontaneously maintain viraemia at low or undetectable levels in the absence of antiretroviral treatment. Furthermore, HIV‐controllers seem to have a superior capacity to spontaneously clear hepatitis C virus (HCV) compared to non HIV‐controllers. Some of these subjects eventually lose HIV‐controller status (transient controllers), whereas some HIV‐controllers show a persistent natural HIV control (persistent controllers). We aimed to analyse whether persistent controllers have superior capacity to spontaneously clear HCV compared to transient controllers., [Methods] We recruited HIV‐controllers from January 1981 up to October 2016 with available antibodies to HCV (anti‐HCV) data (n = 744). Factors associated with HIV spontaneous control in relation to HCV status were analysed in persistent and transient HIV‐controllers with anti‐HCV positive (n = 202 and n = 138 respectively) in comparison with 1700 HCV positive non HIV‐controllers recruited from January 1981 up to March 2018, bivariate and multivariate analyses, following a logistic regression model, were applied. In addition, the factors related to the loss and time to lose HIV‐controller status were explored (n = 744) using Log rank test and Kaplan–Meier curves, in this case the multivariate analysis consisted in a Cox regression model., [Results] A higher frequency of HCV spontaneous clearance was found in persistent HIV‐controllers (25.5%) compared to non‐controllers (10.2%). After adjusting for potential confounders, as sex, age, HIV transmission risk, CD4+ T‐cell nadir and time of follow‐up, HCV clearance was independently associated with persistent HIV spontaneous control (p = 0.002; OR (95% CI) = 2.573 (1.428 to 4.633)), but not with transient spontaneous control (p = 0.119; 1.589 (0.888 to 2.845)). Furthermore, persistent HIV‐controllers were more likely to spontaneously clear the HCV in comparison with transient controllers (p = 0.027; 0.377 (0.159 to 0.893). Finally, not to lose or lengthen the time of losing this control was independently associated with HCV spontaneous clearance (p = 0.010; 0.503 (0.297 to 0.850)., [Conclusions] This study shows an association between spontaneous persistent HIV‐control and HCV spontaneous clearance. The study findings support the idea of preserved immune mechanisms in persistent HIV control implicated in HCV spontaneous clearance. These results highlight persistent HIV‐controllers but not transient controllers as a good model of functional HIV cure., Research funding: Instituto de Salud Carlos III. Grant Numbers: CPII014, /00025, FI14, /00431, PI12, /02283, PI16, /00684, PI19, /01127. Red Temática de Investigación Cooperativa en SIDA. Grant Numbers: RD12, /0017/0029, RD12, /0017/0031, RD16, /0025/0020, RD16, /0025/0013. Consejería de Salud y Bienestar Social of Junta de Andalucía through the Nicolás Monardes program. Grant Number: C‐0032/17. The Spanish Ministry of Education. Grant Number: FPU13/02451. MINECO. Grant Number: 2016‐77894‐R. RIS‐RETIC. Grant Numbers: RD06, /006/0036, RD12, /0017/0028
- Published
- 2020
26. Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure
- Author
-
Concepción Casado, Cristina Gálvez, Cecilio López-Galíndez, Maria Pernas, Laura Tarancon-Diez, Ramon Lorenzo-Redondo, Ezequiel Ruiz-Mateos, Javier Martinez-Picado, Carmen Rodríguez, and Maria Cristina O. Salgado
- Subjects
Epidemiology ,business.industry ,Immunology ,Public Health, Environmental and Occupational Health ,Human immunodeficiency virus (HIV) ,medicine.disease_cause ,Microbiology ,QR1-502 ,Pathogenesis ,Infectious Diseases ,Virology ,Medicine ,Public aspects of medicine ,RA1-1270 ,business ,Control (linguistics) ,Elite controllers - Published
- 2019
27. Increased CD127+ and decreased CD57+ T cell expression levels in HIV-infected patients on NRTI-sparing regimens
- Author
-
Jose L. Jimenez, Miguel C. Leal, M. A. Muñoz-Fernández, R. S. De Pablo-Bernal, Laura Tarancon-Diez, Ezequiel Ruiz-Mateos, Beatriz Dominguez-Molina, Alejandro González-Serna, and Sara Ferrando-Martinez
- Subjects
Adult ,Male ,0301 basic medicine ,Oncology ,medicine.medical_specialty ,T-Lymphocytes ,T cell ,lcsh:Medicine ,HIV Infections ,Peripheral blood mononuclear cell ,General Biochemistry, Genetics and Molecular Biology ,Flow cytometry ,Interleukin-7 Receptor alpha Subunit ,03 medical and health sciences ,Basal (phylogenetics) ,CD57 Antigens ,immune system diseases ,Internal medicine ,medicine ,Homeostasis ,Humans ,Interleukin-7 receptor ,medicine.diagnostic_test ,integumentary system ,business.industry ,Research ,lcsh:R ,virus diseases ,HIV ,General Medicine ,biochemical phenomena, metabolism, and nutrition ,Middle Aged ,030112 virology ,Regimen ,CD127 ,030104 developmental biology ,medicine.anatomical_structure ,NRTI-sparing ,Reverse Transcriptase Inhibitors ,Drug Therapy, Combination ,Female ,business ,Viral load ,CD57 ,CD8 - Abstract
Background NRTIs-sparing regimens exert favourable profiles on T-cell homeostasis associated parameters. Our aim was to analyze the effect of NRTIs sparing regimen (NRTI-sparing-cART) vs NRTIs-containing regimen (NRTI-cART), on T-cell homeostasis associated parameters in naive HIV-infected patients. Methods Biomarkers of cell survival (CD127) and replicative senescence (CD57), were measured by multiparametric flow cytometry for T-cell phenotyping on peripheral blood mononuclear cells (PBMCs) samples just before (baseline) and after 48 weeks of undetectable viral load in patients on NRTI-sparing-cART (N = 13) and NRTI-cART (N = 14). After 48 weeks a subgroup of patients (n = 5) on NRTI-cART switched to NRTI-sparing-cART for another additional 48 weeks. In vitro assays were performed on PBMCs from HIV-uninfected healthy donors exposed or not to HIV. To analyze the independent factors associated with type of cART bivariate and stepwise multivariate analysis were performed after adjusting for basal CD4+, CD8+ and nadir CD4+ T-cell counts. Results After 48 weeks of a NRTI-sparing-cART vs NRTI-cART patients have higher effector memory (EM) CD4+ CD127+ T-cell levels, lower EM CD4+ CD57+ T-cell levels, higher CD8+ CD127+ T-cell levels, lower CD8+ CD57+ T-cell levels and higher memory CD8+ T-cell levels. This effect was confirmed in the subgroup of patients who switched to NRTI-sparing-cART. In vitro assays confirmed that the deleterious effect of a NRTIs-containing regimen was due to NRTIs. Conclusions The implementation of NRTI-sparing regimens, with a favourable profile in CD127 and CD57 T-cell expression, could benefit cART-patients. These results could have potential implications in a decrease in the number of Non-AIDS events. Electronic supplementary material The online version of this article (10.1186/s12967-017-1367-5) contains supplementary material, which is available to authorized users.
- Published
- 2017
28. High CD8 T cell percentage and HCV replication control are common features in HIV-1 controllers and HTLV-2-co-infected patients with a history of injection drug use
- Author
-
Santiago Moreno, Ana Moreno, Carolina Gutierrez, Alejandro Vallejo, Laura Tarancon-Diez, Manuel Leal, María J Pérez-Elías, Fernando Dronda, Beatriz Dominguez-Molina, Ezequiel Ruiz-Mateos, María J. Ruiz-León, Instituto de Salud Carlos III, Red Española de Investigación en SIDA, Ministerio de Educación, Cultura y Deporte (España), and Comunidad de Madrid
- Subjects
Adult ,Male ,Cancer Research ,Multivariate analysis ,Human immunodeficiency virus (HIV) ,HIV Infections ,Hepacivirus ,CD8-Positive T-Lymphocytes ,Virus Replication ,medicine.disease_cause ,Injection drug use ,Tertiary Care Centers ,03 medical and health sciences ,Immune system ,Virology ,Genotype ,medicine ,Humans ,Cytotoxic T cell ,Substance Abuse, Intravenous ,Retrospective Studies ,030304 developmental biology ,0303 health sciences ,Deltaretrovirus Infections ,biology ,Coinfection ,030306 microbiology ,Human T-lymphotropic virus 2 ,CD8 T cell percentage ,RNA ,virus diseases ,Middle Aged ,Viral Load ,HCV RNA load ,HIV-1 controllers ,Cross-Sectional Studies ,Infectious Diseases ,HTLV-2 ,Spain ,Immunology ,Disease Progression ,HIV-1 ,biology.protein ,Female ,Antibody - Abstract
HTLV-2/HIV-1-coinfected patients and HIV-infected patients with natural HIV-1 control show an immune capacity that allows some control of viral infections. These two groups of patients have showed an immune capacity that allows them to have some control over viral infections, very strong control of HIV-1 replication in the case of HIV-1 controllers. The purpose of this retrospective cross-sectional study was to compare viral and immunologic parameters between three cohorts of Caucasian adult HIV-1-infected patients, including HIV-1 controllers (29 patients), HTLV-2/HIV-1 chronic progressors (56 patients), and HIV-1 chronic progressors (101 patients), followed in two different tertiary University Hospitals in Spain. Demographic parameters, nadir CD4 T cell count, CD4 and CD8 T cell counts and percentage, anti-HCV antibodies, HCV RNA load, HCV genotype, HIV-1 RNA loads, and anti-HTLV-2 antibodies were analyzed. HIV-1 controllers and HTLV-2/HIV-1 chronic progressors were younger and with shorter time since HIV-1 diagnosis compared to HIV-1 chronic progressors. HIV-1 controllers and HTLV-2/HIV-1 chronic progressors had significantly higher CD8 T cell percentage (p = 0.002 and p = 0.016, respectively) and lower levels of HCV RNA loads (0.015 and 0.007, respectively) compared to that of HIV-1 chronic progressors. Multivariate analyses showed that gender and HTLV-2 infection were independently associated to HCV RNA load, while only HTLV-2 infection was independently associated to CD8 T cell percentage. The implication of HTLV-2 infection in the control of HIV-1 and HCV infections is worth being further analyze., This work was supported by the Instituto de Salud Carlos III Red Temática de Investigación Cooperativa en Sindrome de Inmunodeficiencia Adquirida (SIDA) (RD016/0025/0001, RD12/0017/0029, RD16/0025/0020 ISCIII-FEDER) and Programa Miguel Servet (CPII014/00025 to ERM); the Spanish Ministry of Education (FPU13/02451 to BDM); Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III FEDER (PI12/02283, PI16/00684 to ERM and FI14/00431 to LTD); Ayudas contratación de ayudantes de investigación y técnicos de laboratorio, Consejería de Educación, Juventud y Deporte de la Comunidad de Madrid (PEJ15/bio/tl-0064 to MJRL).
- Published
- 2019
29. Toll-Like Receptor 7 (TLR-7) and TLR-9 Agonists Improve Hepatitis C Virus Replication and Infectivity Inhibition by Plasmacytoid Dendritic Cells
- Author
-
Ezequiel Ruiz-Mateos, Miguel C. Leal, K. Machmach, Celia Perales, Laura Tarancon-Diez, Esteban Domingo, J. L. Sheldon, Beatriz Dominguez-Molina, and Isabel Gallego
- Subjects
0301 basic medicine ,Carcinoma, Hepatocellular ,Hepatitis C virus ,Immunology ,Antigen presentation ,Cellular Response to Infection ,Hepacivirus ,Biology ,Virus Replication ,medicine.disease_cause ,Antiviral Agents ,Microbiology ,Virus ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Interferon ,Virology ,Tumor Cells, Cultured ,medicine ,Humans ,innate immunity ,Toll-like receptor ,Innate immune system ,Liver Neoplasms ,pDCs ,Interferon-alpha ,hemic and immune systems ,Dendritic Cells ,Acquired immune system ,Hepatitis C ,030104 developmental biology ,Toll-Like Receptor 7 ,Toll-Like Receptor 9 ,030220 oncology & carcinogenesis ,Insect Science ,HCV ,medicine.drug - Abstract
Plasmacytoid dendritic cells (pDCs) are innate immune cells with high antiviral activity triggered by Toll-like receptor 7 (TLR-7) and TLR-9 stimulation. Moreover, they are important mediators between innate and adaptive immunity. Although nowadays there is available an effective therapeutic arsenal against hepatitis C virus (HCV), a protective vaccine is not available. We have analyzed the pDCs’ response to HCV infection in a hepatitis C virus (HCV)-Huh7.5 virus-cell system, which allows completion of the virus infectious cycle. pDCs were cocultured following human immunodeficiency virus (HIV) aldrithiol-2 (AT-2 [TLR-7 agonist]) inactivation and CpG (TLR-9 agonist) stimulation. We employed three virus derivatives—wild-type Jc1, interferon (IFN)-resistant virus IR, and high-replicative-fitness virus P100—in order to explore additional IFN-α-related virus inhibition mechanisms. pDCs inhibited HCV infectivity and replication and produced IFN-α. After TLR-7 and TLR-9 stimulation, inhibition of infectivity and IFN-α production by pDCs were enhanced. TLR-7 stimulation drove higher TNF-related apoptosis-inducing ligand (TRAIL) expression in pDCs. Additionally, TLR-7- and TLR-9-stimulated pDCs exhibited a mature phenotype, improving the antigen presentation and lymph node homing-related markers. In conclusion, pDCs could serve as a drug target against HCV in order to improve antiviral activity and as an enhancer of viral immunization. IMPORTANCE We implemented a coculture system of pDCs with HCV-infected hepatoma cell line, Huh7.5. We used three HCV derivatives in order to gain insight into pDCs’ behavior against HCV and associated antiviral mechanisms. The results with this cell coculture system support the capacity of pDCs to inhibit HCV replication and infectivity mainly via IFN-α, but also through additional mechanisms associated with pDC maturation. We provided evidence that TLR agonists can enhance antiviral pDCs’ function and can induce phenotypic changes that may facilitate the interplay with other immune cells. These findings suggest the possibility of including TLR agonists in the strategies of HCV vaccine development.
- Published
- 2018
30. Improved CD4 T cell profile in HIV-infected subjects on maraviroc-containing therapy is associated with better responsiveness to HBV vaccination
- Author
-
Miguel Genebat, Manuel Leal, Yolanda M. Pacheco, Carmen Lozano, María del Mar del Pozo-Balado, Isaac Rosado-Sánchez, Ezequiel Ruiz-Mateos, Maria del Mar Rodríguez-Méndez, Inés Herrero-Fernández, and Laura Tarancon-Diez
- Subjects
CD4-Positive T-Lymphocytes ,Male ,0301 basic medicine ,lcsh:Medicine ,Apoptosis ,HIV Infections ,medicine.disease_cause ,Logistic regression ,T-Lymphocytes, Regulatory ,Cohort Studies ,Maraviroc ,chemistry.chemical_compound ,Vaccination ,virus diseases ,HBV vaccine ,General Medicine ,Middle Aged ,Viral Load ,Flow Cytometry ,Hepatitis B ,Treg ,hsCRP ,Treatment Outcome ,Anti-Retroviral Agents ,CD4 T-cell ,Regression Analysis ,Female ,medicine.symptom ,Ki67 ,Adult ,Senescence ,Hepatitis B virus ,Recent Thymic Emigrant ,Activation ,Inflammation ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Dendritic cells (DC) ,medicine ,Humans ,Hepatitis B Vaccines ,business.industry ,Research ,lcsh:R ,Dendritic Cells ,Dendritic cell ,CD4 Lymphocyte Count ,030104 developmental biology ,chemistry ,Recent thymic emigrants (RTE) ,Immunology ,Maraviroc (MVC) ,business - Abstract
Background Maraviroc-containing combined antiretroviral therapy (MVC-cART) improved the response to the hepatitis B virus (HBV) vaccine in HIV-infected subjects younger than 50 years old. We aimed here to explore the effect of this antiretroviral therapy on different immunological parameters that could account for this effect. Methods We analysed baseline samples of vaccinated subjects under 50 years old (n = 41). We characterized the maturational subsets and the expression of activation, senescence and prone-to-apoptosis markers on CD4 T-cells; we also quantified T-regulatory cells (Treg) and dendritic cell (DC) subsets. We used binary logistic regression to evaluate the immunological impact of MVC-cART, correlation with MVC exposure and linear regression for association with the magnitude of the HBV vaccine response. Results HIV-infected subjects on MVC-cART prior to vaccination showed increased recent thymic emigrants levels and reduced myeloid-DC levels. A longer exposure to MVC-cART was associated with lower frequencies of Tregs and activated and proliferating CD4 T-cells. Furthermore, the frequencies of activated and proliferating CD4 T-cells were inversely associated with the magnitude of the HBV vaccine response. Conclusion The beneficial effect of MVC-cART in the HBV vaccine response in subjects below 50 years old could be partially mediated by its reducing effect on the frequencies of activated and proliferating CD4 T-cells prior to vaccination. Electronic supplementary material The online version of this article (10.1186/s12967-018-1617-1) contains supplementary material, which is available to authorized users.
- Published
- 2018
31. Improved CD4 T-cell profile and inflammatory levels in HIV-infected subjects on maraviroc-containing therapy is associated with better responsiveness to HBV vaccination
- Author
-
Miguel Genebat, Ezequiel Ruiz-Mateos, Isaac Rosado-Sánchez, Yolanda M. Pacheco, María del Carmen Lozano, María del Mar del Pozo-Balado, Manuel Leal, Maria del Mar Rodríguez-Méndez, Inés Herrero-Fernández, and Laura Tarancon-Diez
- Subjects
Senescence ,Hepatitis B virus ,business.industry ,virus diseases ,Inflammation ,Dendritic cell ,medicine.disease_cause ,Logistic regression ,Vaccination ,chemistry.chemical_compound ,chemistry ,Immunology ,medicine ,Distribution (pharmacology) ,medicine.symptom ,business ,Maraviroc - Abstract
IntroductionWe previously found that a maraviroc-containing combined antiretroviral therapy (MVC-cART) was associated with a better response to the Hepatitis B Virus (HBV) vaccine in HIV-infected subjects younger than 50 years old. We aimed here to extend our previous analysis including immunological parameters related to inflammation, T-cell and dendritic cell (DC) subsets phenotype and to explore the impact of MVC-cART on these parameters.MethodsWe analyzed baseline samples of vaccinated subjects under 50 years old (n=41). We characterized CD4 T-cells according to the distribution of their maturational subsets and the expression of activation, senescence and prone-to-apoptosis markers; we also quantified Treg-cells and main DC subsets. Linear regressions were performed to determine the impact of these variables on the magnitude of vaccine response. Binary logistic regressions were explored to analyze the impact of MVC-cART on immunological parameters. Correlations with the time of MVC exposure were also explored.ResultsMVC-cART remained independently associated with HBV-vaccine responsiveness even after adjusting by immunological variables. The %CD4+CD25hiFoxP3+ki67+ and %pDCs were also independently associated. Moreover, HIV-infected subjects on MVC-containing therapy prior to vaccination showed lower inflammatory levels, activated CD4 T-cells and frequency of Treg cells and higher frequency of recent thymic emigrants.ConclusionTreg-cell levels negatively impacted the HBV-vaccine response, whereas higher pDCs levels and a MVC-cART prior to vaccination were associated with better responsiveness. These factors together with the improved phenotypic CD4 T-cell profile and the lower inflammatory levels found in subjects with a MVC-cART prior HBV vaccination could contribute to their enhanced vaccine response.
- Published
- 2018
- Full Text
- View/download PDF
32. Role of toll-like receptor 4 Asp299Gly polymorphism in the development of cardiovascular diseases in HIV-infected patients
- Author
-
Isaac Rosado-Sánchez, Jose L. Jimenez, Laura Tarancon-Diez, Miguel Genebat, Ana I. Alvarez-Rios, María-Ángeles Muñoz-Fernández, Rebeca S. de Pablo-Bernal, Manuel Leal, and Ezequiel Ruiz-Mateos
- Subjects
0301 basic medicine ,Adult ,Male ,Immunology ,Single-nucleotide polymorphism ,HIV Infections ,030204 cardiovascular system & hematology ,Polymorphism, Single Nucleotide ,Proinflammatory cytokine ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Diabetes mellitus ,medicine ,Immunology and Allergy ,SNP ,Humans ,Genetic Predisposition to Disease ,business.industry ,Monocyte ,Bacterial pneumonia ,Odds ratio ,medicine.disease ,Toll-Like Receptor 4 ,030104 developmental biology ,Infectious Diseases ,medicine.anatomical_structure ,Cardiovascular Diseases ,TLR4 ,Female ,business - Abstract
[Objective] Cardiovascular diseases (CVDs) are one of the main causes of morbimortality in HIV-infected patients on suppressive antiretroviral therapy. The objective of this work was to evaluate the role of single nucleotide polymorphisms (SNPs) in lipopolysaccharide (LPS) Toll-like receptor 4 (TLR4) and CVDs occurrence in HIV-infected patients. Additionally, the functional consequences of carrying these SNPs were analyzed., [Methods] The association of TLR4 SNPs, Asp299Gly/Thr399Ile with CVDs occurrence was analyzed using multivariate logistic regression models. Clinical, immunological, and traditional cardiovascular risk factors were used as covariates. The monocyte phenotype and response were assessed by multiparametric flow cytometry comparing carriers with noncarriers of this SNP., [Results] Asp299Gly SNP, assayed in 253 HIV-infected patients, was independently associated with the occurrence of CVDs after adjusting for CD4+ T-cell nadir, HCV-coinfection, bacterial pneumonia, diabetes mellitus, and traditional cardiovascular risk factors [odds ratio (confidence interval 95%) = 3.672 (1.061–12.712), P = 0.04). Carriers of Asp299Gly SNP showed higher percentage of patrolling and intermediate monocytes producing a proinflammatory combination of cytokines compared with noncarriers (P = 0.037 and P = 0.046, respectively). Intermediate monocyte subset levels correlated with soluble interleukin-6 levels only in carriers (r = 0.89; P = 0.01)., [Conclusion] TLR4 Asp299Gly polymorphism is independently associated with the occurrence of CVDs in HIV-infected patients. The proinflammatory profile associated to this variant could be involved in the development of atherosclerotic pathologies.
- Published
- 2018
33. Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response
- Author
-
Manuel Leal, Isaac Rosado-Sánchez, Ezequiel Ruiz-Mateos, María José Polaino, Miguel Genebat, Maria del Mar Rodríguez-Méndez, Inés Herrero-Fernández, María del Carmen Lozano, Yolanda M. Pacheco, María Ángeles Muñoz-Fernández, Laura Tarancon-Diez, [Herrero-Fernandez, Ines] Univ Seville, CSIC, Virgen Rocio Univ Hosp, Lab Immunovirol,Inst Biomed Seville IBiS, Seville, Spain, [Pacheco, Yolanda M.] Univ Seville, CSIC, Virgen Rocio Univ Hosp, Lab Immunovirol,Inst Biomed Seville IBiS, Seville, Spain, [Genebat, Miguel] Univ Seville, CSIC, Virgen Rocio Univ Hosp, Lab Immunovirol,Inst Biomed Seville IBiS, Seville, Spain, [del Mar Rodriguez-Mendez, Maria] Univ Seville, CSIC, Virgen Rocio Univ Hosp, Lab Immunovirol,Inst Biomed Seville IBiS, Seville, Spain, [Jose Polaino, Maria] Univ Seville, CSIC, Virgen Rocio Univ Hosp, Lab Immunovirol,Inst Biomed Seville IBiS, Seville, Spain, [Rosado-Sanchez, Isaac] Univ Seville, CSIC, Virgen Rocio Univ Hosp, Lab Immunovirol,Inst Biomed Seville IBiS, Seville, Spain, [Tarancon-Diez, Laura] Univ Seville, CSIC, Virgen Rocio Univ Hosp, Lab Immunovirol,Inst Biomed Seville IBiS, Seville, Spain, [Ruiz-Mateos, Ezequiel] Univ Seville, CSIC, Virgen Rocio Univ Hosp, Lab Immunovirol,Inst Biomed Seville IBiS, Seville, Spain, [Leal, Manuel] Univ Seville, CSIC, Virgen Rocio Univ Hosp, Lab Immunovirol,Inst Biomed Seville IBiS, Seville, Spain, [del Carmen Lozano, Maria] Virgen Rocio Univ Hosp, Microbiol Serv, Seville, Spain, [Angeles Munoz-Fernandez, Maria] Gen Univ Hosp Gregorio Maranon, Hlth Res Inst Gregorio Maranon, Mol Immunobiol Lab, Spanish HIV HGM BioBank, Madrid, Spain, [Angeles Munoz-Fernandez, Maria] Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Madrid, Spain, ViiV Healthcare S.L., Fondo de Investigacion Sanitaria (FIS), Fondos Europeos para el Desarrollo Regional (FEDER), Junta de Andalucia, Consejeria de Economia, Innovacion, Ciencia y Empleo (Proyecto de Investigacion de Excelencia), Spanish AIDS Research Network of Excellence, Fondo de Investigacion Sanitaria through 'Miguel Servet' programs, Consejeria de Salud y Bienestar Social of Junta de Andalucia through 'Nicolas Monardes' program, Instituto de Salud Carlos III (PFIS), ViiV Healthcare, Instituto de Salud Carlos III, European Commission, Junta de Andalucía, and Red Española de Investigación en SIDA
- Subjects
0301 basic medicine ,Male ,maraviroc ,Nonresponders ,medicine.disease_cause ,Maraviroc ,chemistry.chemical_compound ,0302 clinical medicine ,vaccine ,Pharmacology (medical) ,030212 general & internal medicine ,Progression ,Vaccination ,virus diseases ,Hepatitis B ,Middle Aged ,Hepatitis a virus ,Titer ,Infectious Diseases ,Anti-Retroviral Agents ,Hiv-infected patients ,Combined antiretroviral treatment ,Female ,Immune-responses ,Cart ,Adult ,Hepatitis B virus ,Efficacy ,Immunosenescence ,High-rates ,Immunization, Secondary ,Antiviral Agents ,03 medical and health sciences ,hepatitis A virus ,medicine ,Adults ,Humans ,Hepatitis B Vaccines ,Hepatitis B Antibodies ,combined antiretroviral treatment ,Pharmacology ,business.industry ,medicine.disease ,HIV infection ,Virology ,Antiretroviral therapy ,digestive system diseases ,Blockade ,030104 developmental biology ,chemistry ,Hepatitis A virus ,business ,Vaccine - Abstract
The response to the HBV vaccine in HIV-infected patients is deficient. Our aim was to analyze whether a suppressive combined antiretroviral treatment (cART) containing maraviroc (MVC-cART) was associated with a better response to HBV vaccine. Fifty-seven patients on suppressor cART were administered the HBV vaccine. The final response, the early response, and the maintenance of the response were assessed. An anti-HBs titer of >10 mIU/ml was considered a positive response. A subgroup of subjects was simultaneously vaccinated against hepatitis A virus (HAV). Lineal regression analyses were performed to determine demographic, clinical, and immunological factors associated with the anti-HBs titer. Vaccine response was achieved in 90% of the subjects. After 1 year, 81% maintained protective titers. Only simultaneous HAV vaccination was independently associated with the magnitude of the response in anti-HBs titers, with a P value of 0.045 and a regression coefficient (B) [95% confident interval (CI)] of 236 [5 to 468]. In subjects ≤50 years old (n = 42), MVC-cART was independently associated with the magnitude of the response (P = 0.009; B [95% CI], 297 [79 to 516]) together with previous vaccination and simultaneous HAV vaccination. High rates of HBV vaccine response can be achieved by revaccination, simultaneous HAV vaccination, and administration of cARTs including MVC. MVC may be considered for future vaccination protocols in patients on suppressive cART., This study was funded by an investigator-initiated research grant from ViiV Healthcare S.L. (grant number 205644) and by grants from the Fondo de Investigación Sanitaria (FIS; PI14/01693; PI16/01863), cofunded by Fondos Europeos para el Desarrollo Regional (FEDER) and the Junta de Andalucía, Consejería de Economía, Innovación, Ciencia y Empleo (Proyecto de Investigación de Excelencia; CTS2593). The Spanish AIDS Research Network of Excellence also supported this study (RD16/0025/0019). E.R.-M. and Y.M.P. were supported by the Fondo de Investigación Sanitaria through the ‘Miguel Servet’ programs (CPII014/00025 and CPII13/00037, respectively). Y.M.P. was supported by the Consejería de Salud y Bienestar Social of Junta de Andalucía through the ‘Nicolás Monardes’ program (C-0010/13). L.T.-D. was supported by Instituto de Salud Carlos III (PFIS program; FI00/00431).
- Published
- 2018
34. Increased frequencies of Th17 cells and IL17a-producing regulatory T-cells preceding the immunodiscordant response to antiretroviral treatment
- Author
-
Francisco J. Vera-Méndez, Manuel Leal, David Dalmau, Yolanda M. Pacheco, Inés Herrero-Fernández, Isaac Rosado-Sánchez, Laura Tarancon-Diez, Santiago Moreno, and José Antonio Iribarren
- Subjects
0301 basic medicine ,Microbiology (medical) ,Cart ,Adult ,Male ,medicine.medical_specialty ,CD4 antigen ,Anti-HIV Agents ,HIV Infections ,Biology ,Peripheral blood mononuclear cell ,T-Lymphocytes, Regulatory ,Flow cytometry ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Pharmacotherapy ,immune system diseases ,Internal medicine ,Antiretroviral Therapy, Highly Active ,medicine ,Antiretroviral treatment ,Humans ,medicine.diagnostic_test ,Interleukin-17 ,virus diseases ,hemic and immune systems ,Middle Aged ,CD4 Lymphocyte Count ,030104 developmental biology ,Infectious Diseases ,Endocrinology ,nervous system ,chemistry ,Immunology ,Cytokines ,Th17 Cells ,IL17A ,Homeostasis ,030215 immunology - Abstract
Summary Background Despite the fact that antiretroviral therapy (cART) suppresses HIV-viremia, an adequate CD4 T-cell recovery is not always achieved (immunodiscordant response to cART). IL17a-producing CD4 T-cells (Th17) constitutes an important subset involved in the preservation of mucosal surfaces integrity, which depletion has been associated with disease progression in HIV-infection. However, whether Th17 frequency at cART initiation is associated with a poor CD4 T-cell recovery has not been yet explored. Our aim was to explore whether the Th17 cells and other IL17a-producing T-cell subsets at cART initiation were associated with a subsequent immunodiscordant response to cART. Methods We selected pre-cART samples of antiretroviral-naive subjects with and without a low CD4 recovery after cART (LR-subjects and HR-subjects, respectively). Peripheral blood mononuclear cells (PBMCs) were stimulated with PMA/ionomycine, and the production of several cytokines including IL17a was analyzed by flow cytometry. Results A trend to higher Th17 ( p = 0.05) and increased frequencies of IL17a-producing Treg ( p = 0.011) was found in LR-subjects before cART onset. Despite increased frequencies of both Treg and Th17 in LR-subject at cART initiation, no alteration of Treg/Th17 ratio was observed. While polifunctional profile of CD4 T-cells was not different, frequencies of CD4 T-cells producing cytokine-combinations including IL17a were increased in LR-subjects. Conclusion Increased frequencies of Th17, IL17a-producing Treg and CD4 T-cells producing specific IL17a-containing combinations of cytokines, precede the immunodiscordant response to cART, suggesting a potential contribution of these subsets in such anomalous response to cART.
- Published
- 2017
35. HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers
- Author
-
Laura Capa, José Alcamí, Cristina Tural, Bruce D. Walker, Cristina Abad-Molina, Francisco Vidal, K. Machmach, Del Romero J, Manuel Leal, Carmen Rodríguez, Ezequiel Ruiz-Mateos, Ramírez de Arellano E, Laura Tarancon-Diez, Del Val M, Stephane Hua, María Francisca González-Escribano, Mathias Lichterfeld, Beatriz Dominguez-Molina, Pompeyo Viciana, Esther Rodríguez-Gallego, Goñi Jm, Santiago Moreno, Xu G. Yu, Univ Seville, Virgen Rocio Univ Hosp, CSIC,Lab Immunobiol, Inst Biomed Seville,IBiS,Clin Unit Infect Dis Mic, Seville, Spain, [Hua, Stephane] MIT & Harvard, Ragon Inst MGH, Cambridge, MA USA, [Yu, Xu G.] MIT & Harvard, Ragon Inst MGH, Cambridge, MA USA, [Walker, Bruce D.] MIT & Harvard, Ragon Inst MGH, Cambridge, MA USA, [Lichterfeld, Mathias] MIT & Harvard, Ragon Inst MGH, Cambridge, MA USA, [Hua, Stephane] Harvard Med Sch, Boston, MA USA, [Yu, Xu G.] Harvard Med Sch, Boston, MA USA, [Walker, Bruce D.] Harvard Med Sch, Boston, MA USA, [Lichterfeld, Mathias] Harvard Med Sch, Boston, MA USA, [Hua, Stephane] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA, [Yu, Xu G.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA, [Walker, Bruce D.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA, [Lichterfeld, Mathias] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA, [Hua, Stephane] Brigham & Womens Hosp, Div Infect Dis, Boston, MA USA, [Yu, Xu G.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA USA, [Walker, Bruce D.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA USA, [Lichterfeld, Mathias] Brigham & Womens Hosp, Div Infect Dis, Boston, MA USA, [Abad-Molina, Cristina] Virgen Rocio Univ Hosp, IBiS, Inst Biomed Seville, Immunol Lab, Seville, Spain, [Gonzalez-Escribano, Maria Francisca] Virgen Rocio Univ Hosp, IBiS, Inst Biomed Seville, Immunol Lab, Seville, Spain, [Rodriguez-Gallego, Esther] Univ Rovira & Virgili, Hosp Univ Tarragona Joan 23, IISPV, Tarragona, Spain, [Vidal, Francesc] Univ Rovira & Virgili, Hosp Univ Tarragona Joan 23, IISPV, Tarragona, Spain, [Machmach, Kawthar] Univ Calif Davis, Dept Med Microbiol & Immunol, Davis, CA USA, [Tural, Cristina] Hosp Badalona Germans Trias & Pujol, Fundacio Lluita Sida Fundacio Irsicaixa, Badalona, Spain, [Moreno, Santiago] Univ Alcala Henares, Hosp Ramon & Cajal, Inst Ramon & Cajal Invest Sanitaria, Dept Infect Dis, Madrid, Spain, [de Arellano, Elena Ramirez] Complejo Hosp Navarra, Dept Endocrinol, Navarra, Spain, [del Val, Margarita] Complejo Hosp Navarra, Dept Endocrinol, Navarra, Spain, [del Val, Margarita] Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Inmunol Viral, Madrid, Spain, [Del Romero, Jorge] Ctr Biol Mol Severo Ochoa, Madrid, Spain, [Rodriguez, Carmen] Ctr Biol Mol Severo Ochoa, Madrid, Spain, [Capa, Laura] Inst Salud Carlos III, AIDS Immunopathol Unit, Madrid, Spain, [Alcami, Jose] Inst Salud Carlos III, AIDS Immunopathol Unit, Madrid, Spain, [Walker, Bruce D.] Howard Hughes Med Inst, Madrid, Spain, Instituto de Salud Carlos III Red Tematica de Investigacion Cooperativa en Sindrome de inmunodeficiencia humana (SIDA), Spanish Ministry of Education, Ministerio de Economia y Competitividad (MINECO)/Fondos Europeos para el Desarrollo Regional (FEDER), Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III FEDER, Programa de Suport als Grups de Recerca AGAUR (Agencia de Gestio d'Ajuts Universitaris i de Recerca), Gilead Fellowship Program, and National Institutes of Health
- Subjects
0301 basic medicine ,Microbiology (medical) ,Oncology ,HLA-B*57 ,Adult ,Male ,medicine.medical_specialty ,IFNL4 ,Viremia ,HIV Infections ,Human leukocyte antigen ,Polymorphism, Single Nucleotide ,Cohort Studies ,03 medical and health sciences ,Young Adult ,Internal medicine ,Genotype ,medicine ,HLA-B Antigens ,HLA-B(star)57 ,Major Article ,Humans ,Genetic Predisposition to Disease ,business.industry ,Interleukins ,Haplotype ,HIV-controllers ,Elite ,HIV controllers ,virus diseases ,medicine.disease ,HLA-B ,030104 developmental biology ,Infectious Diseases ,Plasmacytoid dendritic cells ,Il28b ,Cohort ,Disease Progression ,HIV-1 ,Clearance ,Female ,Therapy ,progression ,business ,CD8 - Abstract
Background HIV-1-controllers maintain HIV-1 viremia at low levels (normally 500 cells/mm3 for more than 7 years after HIV-1 diagnosis) versus non-LTNP-C, who developed CD4+T-cells counts
- Published
- 2017
36. Long-term Persistent Elite HIV-controllers: The Right Model of Functional Cure
- Author
-
Pompeyo Viciana, Laura Tarancon-Diez, Luis F. López-Cortés, Ezequiel Ruiz-Mateos, and Beatriz Dominguez-Molina
- Subjects
0301 basic medicine ,Gerontology ,Adult ,Male ,HLA B*07 C*07 ,T-Lymphocytes ,030106 microbiology ,Human immunodeficiency virus (HIV) ,lcsh:Medicine ,HIV Infections ,HIV-1 DNA ,Biology ,medicine.disease_cause ,General Biochemistry, Genetics and Molecular Biology ,HIV Long-Term Survivors ,03 medical and health sciences ,Sexual and Gender Minorities ,medicine ,Humans ,Homosexuality, Male ,Phylogeny ,lcsh:R5-920 ,Immune activation ,lcsh:R ,General Medicine ,Term (time) ,Incomplete western blot ,030104 developmental biology ,Sexual Partners ,Elite control ,Elite ,Commentary ,HIV-1 ,Partner ,lcsh:Medicine (General) ,Genetic Background ,Research Paper - Abstract
Background We describe a homosexual man who strongly controlled HIV-1 for ten years despite lack of protective genetic background. Methods HIV-1 DNA was measured in blood and other tissues. Cell susceptibility was evaluated with various strains. HIV-1-specific (CD4 and CD8 activation markers and immune check points) and NK cells responses were assessed; KIRs haplotypes and HLA alleles were determined. Findings Two HIV-1 RNA copies/mL of plasma were detected in 2009, using an ultra-sensitive assay. HIV-DNA was detected at 1.1 and 2 copies/106 PBMCs in 2009 and 2015 respectively, at 1.2 copies/106 cells in rectal cells in 2011. WBs showed weak reactivity with antibodies to gp160, p55 and p25 from 2007 to 2014, remaining incomplete in 2017. CD4 T cells were susceptible to various strains including HIVKON, a primary isolate of his own CRF02_AG variant. CD8 T cells showed a strong poly-functional response against HIV-Gag, producing mainly IFN-γ; a robust capacity of antibody-dependant cell cytotoxicity (ADCC) was observed in NK cells. Case patient was group B KIR haplotype. Neutralizing antibodies were not detected. CD4 and CD8 blood T cells showed normal proportions without increased activation markers. Phylogenetic analyses identified the same CRF02_AG variant in his partner. The patient and his partner were heterozygous for the CCR5ΔD32 deletion and shared HLA-B*07, C*07 non-protective alleles. Interpretation This thorough description of the natural history of an individual controlling HIV-1 in various compartments for ten years despite lack of protective alleles, and of his partner, may have implications for strategies to cure HIV-1 infection., Highlights • We described a MSM, elite controller despite pejorative genetic background. • The patient had two HLA pejoratives alleles and no protective alleles. • The partner was infected by the same strain. • The genetic backgrounds of the patient and partner, and the virus could interact with each other to lead to elite control. We considered all the evidence about elite control, HLA, ADCC and NK, using Medline/PubMed. We described a MSM, elite controller despite non-protective genetic background, explored extensively the patient: sequential WBs, RNA in plasma (ultrasensitive assay), DNA in PBMC/GALT, cell susceptibility, HIV-1 responses in PBMC/LNMC, neutralizing antibodies, CD3-CD56 + NK, ADCC, KIRs. He had one HLA pejorative and no protective alleles. The partner was infected by the same strain, his genetic background was studied. The genetic background of the exposed person, of the source, and the viral strain could interact with each other to lead to elite control.
- Published
- 2018
37. 5 Identification of different HIV-controller phenotypes: looking for the right model of functional cure
- Author
-
Laura Tarancon-Diez, Cristina Abad-Molina, Mathias Lichterfeld, X.G. Yung, Ezequiel Ruiz-Mateos, Stephane Hua, Manuel Leal, Beatriz Dominguez-Molina, E. Rodriguez, and Francisco Vidal
- Subjects
Epidemiology ,Computer science ,Immunology ,Public Health, Environmental and Occupational Health ,Human immunodeficiency virus (HIV) ,medicine.disease_cause ,Microbiology ,Phenotype ,QR1-502 ,Identification (information) ,Infectious Diseases ,Control theory ,Virology ,medicine ,Public aspects of medicine ,RA1-1270 - Published
- 2016
38. Improved CD4 T cell profile in HIV-infected subjects on maraviroc-containing therapy is associated with better responsiveness to HBV vaccination
- Author
-
Inés Herrero-Fernández, Isaac Rosado-Sánchez, Miguel Genebat, Laura Tarancón-Díez, María Mar Rodríguez-Méndez, María Mar Pozo-Balado, Carmen Lozano, Ezequiel Ruiz-Mateos, Manuel Leal, and Yolanda M. Pacheco
- Subjects
Maraviroc (MVC) ,CD4 T-cell ,Ki67 ,Activation ,Treg ,hsCRP ,Medicine - Abstract
Abstract Background Maraviroc-containing combined antiretroviral therapy (MVC-cART) improved the response to the hepatitis B virus (HBV) vaccine in HIV-infected subjects younger than 50 years old. We aimed here to explore the effect of this antiretroviral therapy on different immunological parameters that could account for this effect. Methods We analysed baseline samples of vaccinated subjects under 50 years old (n = 41). We characterized the maturational subsets and the expression of activation, senescence and prone-to-apoptosis markers on CD4 T-cells; we also quantified T-regulatory cells (Treg) and dendritic cell (DC) subsets. We used binary logistic regression to evaluate the immunological impact of MVC-cART, correlation with MVC exposure and linear regression for association with the magnitude of the HBV vaccine response. Results HIV-infected subjects on MVC-cART prior to vaccination showed increased recent thymic emigrants levels and reduced myeloid-DC levels. A longer exposure to MVC-cART was associated with lower frequencies of Tregs and activated and proliferating CD4 T-cells. Furthermore, the frequencies of activated and proliferating CD4 T-cells were inversely associated with the magnitude of the HBV vaccine response. Conclusion The beneficial effect of MVC-cART in the HBV vaccine response in subjects below 50 years old could be partially mediated by its reducing effect on the frequencies of activated and proliferating CD4 T-cells prior to vaccination.
- Published
- 2018
- Full Text
- View/download PDF
39. Altered Expression of CD300a Inhibitory Receptor on CD4+ T Cells From Human Immunodeficiency Virus-1-Infected Patients: Association With Disease Progression Markers
- Author
-
Joana Vitallé, Iñigo Terrén, Leire Gamboa-Urquijo, Ane Orrantia, Laura Tarancón-Díez, Miguel Genebat, Ezequiel Ruiz-Mateos, Manuel Leal, Susana García-Obregón, Olatz Zenarruzabeitia, and Francisco Borrego
- Subjects
CD300 ,CD300a ,human immunodeficiency virus-1 ,CD4 T cells ,PD1 ,Immunologic diseases. Allergy ,RC581-607 - Abstract
The ability of the CD300a inhibitory receptor to modulate immune cell functions and its involvement in the pathogenesis of many diseases has aroused a great interest in this molecule. Within human CD4+ T lymphocytes from healthy donors, the inhibitory receptor CD300a is differentially expressed among different T helper subsets. However, there are no data about the expression and regulation of CD300a receptor on CD4+ T cells from human immunodeficiency virus (HIV)-1-infected patients. The objective of this study was to investigate the expression of CD300a on CD4+ T cells from HIV-infected patients on suppressive combined antiretroviral therapy (cART) and cART naïve patients. Our results have demonstrated that the expression levels of this inhibitory receptor were higher on CD4+ T cells from HIV-1 infected subjects compared with healthy donors, and that cART did not reverse the altered expression of CD300a receptor in these patients. We have observed an increase of CD300a expression on both PD1+CD4+ and CD38+CD4+ T cells from HIV-1 infected people. Interestingly, a triple positive (CD300a+PD1+CD38+) subset was expanded in naïve HIV-1 infected patients, while it was very rare in healthy donors and patients on cART. Finally, we found a negative correlation of CD300a expression on CD4+ T lymphocytes and some markers associated with HIV-1 disease progression. Thus, our results show that HIV-1 infection has an impact in the regulation of CD300a inhibitory receptor expression levels, and further studies will shed light into the role of this cell surface receptor in the pathogenesis of HIV infection.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.